Introduction: Natural Killer (NK) cells are cytotoxic lymphocytes of the innate immune system capable of targeting virally transformed and tumor cells without prior sensitization. They have shown to be effective at targeting malignant cells without being direct effectors of graft-versus-host disease in both a transplantation setting and as an NK cell therapy alone. There have been numerous clinical trials using NK cells as an adoptive immunotherapy in both hematological and solid malignancies. These have shown NK cell immunotherapy to be safe however efficacy has been inconsistent. Material (or patients) and methods: In order to strive towards an effective and robust clinical therapy we hypothesize that proliferation, persistence and activation of NK cells in vivo is fundamental for the development of a clinically relevant cellular product that will be able to target tumor cells efficiently in patients. Our group has previously shown that frozen CD34 + cells isolated from umbilical cord blood (UCB) are the most favorable source of stem cells to differentiate functional NK cells in vitro. Producing large cell numbers capable of secreting high levels of IFN-g and killing leukemic cell lines in vitro. We therefore tested whether the differentiated NK cells are capable of proliferating and getting activated following further cytokine stimulation and if they are able to persist in vivo to target and eliminate leukemic cells. We also assessed if the cells could be frozen and thawed whilst still maintaining functionality to allow for the production of a readily available off-the-shelf cellular product. Results: We found that the differentiated NK cells could respond to interleukin-2 and proliferate in vitro to the same degree as adult peripheral blood NK cells. This suggests that the cells can further respond to cytokines and proliferate once injected into the patient. The function of the differentiated cells was unaffected by cryopreservation allowing for multiple infusions at different time points of the same NK product. The differentiated NK cells could kill leukemic cells and more importantly could persist for longer and in higher numbers in vivo over other sources of NK cells, indicative of improved survival post infusion. Additionally we assessed pre-activation of the cells by priming the differentiated NK cells using CTV-1 lysate. In comparison to resting controls this consistently led to higher levels of killing of patient leukemic blasts in vitro, however this activation step was not required to observe killing of patient AML blasts in vivo. This indicates that the cells would not require prior activation before infusion resulting in a cellular therapy that was more economical and more easily translatable to the clinic. Conclusion: In conclusion, we are able to generate and cryopreserve NK cells from UCB hematopoietic stem cells in high numbers allowing for multiple infusions that are highly cytotoxic towards tumor cells. These cells can further proliferate in response to additional cytokines and have a clear survival advantage in vivo over other sources of NK cells.
This provides the potential for the development of a robust NK cell immunotherapy which can not only prevent infection post transplantation but also target malignancies in their own right to prevent relapse. Disclosure of Interest: None declared. Introduction: Allogeneic hematopoietic stem cell transplantation (SCT) is a potentially curative option for patients with lymphoproliferative disorders such as Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL). For patients who relapse or have refractory disease after SCT, the use of donor lymphocyte infusion (DLI) represent an important part of the strategy to enhance graft-versus-lymphoma effect (GvL) . In this study we evaluate how DLI is able to control the disease in patients with lymphoma who relapse or have persistent disease after SCT. Material (or patients) and methods: Between February 2001 and July 2012, 7 patients (3 males) with advanced lymphoma (high grade NHL n = 5, HL n = 2) previously treated with SCT received DLI as treatment for progressive or relapsed disease. The median age was 35 (21-52) years at time of SCT. Three of them underwent previous autologous SCT. All patients were transplanted with PBSC, 6 from HLA identical donor and 1 from an unrelated one. Conditioning was myeloablative in 1 and reduced intensity in 6. GvHD prophylaxis included Cyclosporine and short course methotrexate in all patients.
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Results: No patient developed DLI-related aplasia or acute GvHD after DLI. Limited chronic GvHD was observed in only 2 patients. Three patients had no response to DLI and died for progression of their lymphoma. Four patients had sustained complete response with persistent and continued disappearance of the lymphoma. The cumulative response rates after DLI to treat relapse or persistent disease after SCT were 3/4 (75%) and 1/3 (33%), respectively. No correlation was observed between CD3+ cell dose infused and disease response. Both patients who developed DLI-related chronic GvHD had complete response. All four patients who achieved complete response after DLI are still alive and disease-free after a median follow-up of 11 (9-12) years. Conclusion: These data support the existence of a clinically significant GvL effect in high-grade NHL and aggressive HL suggesting that DLI is an effective treatment able to induce long-term remission without severe GvHD in patients with very poor prognosis. A DLI program should always be considered for patients with lymphoma who show persistent disease or relapse after SCT. Disclosure of Interest: None declared.
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Human platelet lysate pathogen reduced through additive-free short-wave UV light irradiation retains its optimal efficacy for the expansion of human bone marrow mesenchymal stem cells Introduction: We recently developed and characterized a standardized and clinical grade human Platelet Lysate (hPL) that constitutes an advantageous substitute for fetal bovine serum for human mesenchymal stem cell (hMSC) expansion required in cell therapy procedures, avoiding xenogenic risks (virological and immunological) and ethical issue. Because of the progressive use of pathogen reduced (PR) labile blood components, we evaluated the impact of the novel procedure THERAFLEX UV-Platelets for pathogen reduction on hPL quality (growth factors content) and efficacy (as a medium supplement for hMSC expansion). This technology is based on short-wave ultraviolet light (UV-C) and has the main advantage not to need the addition of any photosensitizing additive compounds (that might secondary interfere with hMSCs). Material (or patients) and methods: We applied THERAFLEX UV-Platelets procedure on fresh platelet concentrates (PCs) suspended in platelet additive solution and prepared hPL from these treated PCs. We compared the quality and efficacy of PRhPL with the corresponding non-PR ones. Results: We showed no impact on the content in 5 cytokines tested (EGF, bFGF, PDGF-AB, VEGF and IGF) and a significant decrease in TGF-b1 (-21%, n = 16, P o0.01). We performed large scale culture of hMSCs during 3 passages and showed that hPL or PR-hPL at 8% triggered comparable hMSC proliferation than FBS at 10% plus bFGF (n = 3). Moreover, after proliferation of hMSCs in hPL or PR-hPL containing medium, their profile of membrane marker expression, their clonogenic potential and immunosuppressive properties were maintained, in comparison with hMSCs cultured in FBS conditions. The potential to differentiate in adipogenic and osteogenic lineages of hMSCs cultured in parallel in the 3 conditions remained also identical.
Conclusion:
In conclusion, we demonstrated the feasibility to use UV-C treatment to subsequently obtain pathogen reduced hPL, while preserving its optimal quality and efficacy for hMSC expansion for cell therapy applications. Introduction: In patients with myeloma, it might be necessary to perform more than one autologous hematopoietic stem cell transplantations (ASCT). At our centre, we have been have asked to refreeze parts of autologous hematopoietic stem cells (HSC) units with high cell numbers, that already have been stored for several years. The idea is to use the refrozen part of the cells if there is a need for re-transplantation. This raises the question of the viability of the graft. Material (or patients) and methods: The aim of the study was to analyze the effect of refreezing on HSC regarding the amount of CD34+ cells, cell viability, apoptosis and regeneration ability. HSC products from ten deceased patients, stored for more than 8 years, were analyzed regarding the amount of CD34+ cells, cell viability measured with 7-AAD and apoptosis measured with Annexin V. We used flowcytometry for the analysis. The regeneration ability of HSC was analyzed with colony forming units. (01/2015 -11/2015) . The volume of the collected cord blood was compared as well as quality parameters such as cell numbers (TNC) before processing and CD34+ cell content post-processing, by an independent Samples T-test. The level of significance was set for a p-value o 0.05. Results: Mean volume of UCB collected after cesarean section was significantly higher compared to UCB volumes collected after vaginal deliveries (Po 0.0001) (table 1) . No statistically significant difference between quality markers such as cell count and CD34+ count (table 1) could be detected. Conclusion: Cord blood collection after cesarean route of delivery showed a larger collection volume than vaginal delivery. A possible explanation could be that, as the baby is placed above the placenta after the cesarean section, clamping the cord above the placenta possibly causes a downward flow of blood into the umbilical cord, which may result in a greater volume of UCB collected (Nunes & Zandavalli, 2015) . Despite the difference in collected volume, UCB units after cesarean sections seem to contain similar progenitor content compared to vaginal deliveries as Results are expressed as mean ± SD.
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described in the literature (Askari et al, 2005) . In utero UCB collections after cesarean sections are feasible, but further studies are needed to investigate the impact of the type of delivery on quality of the cord blood units. Results: In this overview were discussed Overall survival (OS), Disease free survival (DFS) in different groups, the factors for successful control of the underlying disease, the risks and therapy related complications. In the allogeneic group are considered causes of early death: transplant related mortality (N = 4), death from relapse (N = 5), death from GvHD ( N = 14).
Conclusion:
The results showed an increase number of both autologous and allogeneic transplants -a global trend. The low TRM proves that this high-tech procedure leads to increase OS in some patients and increase their chances for a long DFS. Disclosure of Interest: None declared. Introduction: Pneumocystis jirovecii pneumonia (PJP) is important cause of mortality and morbidity in immunocompromised patients with especially acquired immunodeficiency syndrome (AIDS),and others like hematopoietic stem cell tranplantion or hematologic malignancies. Even though pneumothorax is an expected complication during PJP, pneumomediastinum is quite rare. We report a case of spontaneous pneumomediastinum during treatment of late onset P.jirovecii pneumonia in an allogeneic hematopoietic stem cell tranplant recipient. Material (or patients) and methods: Case Report 23-year-old male patient who underwent allogeneic hematopoietic stem cell tranplantation sixteen months ago, admitted to bone marrow transplantation clinic for shortness of breath. There was widespread rhonchi in bilateral lungs. Patient had no fever with arterial blood gase oxygen level measured as SaO2 89%. Computed tomography showed significant consolidation lung areas of in both upper lobe ( Figure 1 ). Pneumocystis jirovecii pneumonia diagnosis was considered so that high TMP-SMX doses intravenously with 1 mg/kg methylprednisolone was started. Piperacillin-tazobactam added to therapy as bacterial pneumonia can not be ruled out. In the fifth day of treatment, arterial blood gas SaO2 was 95%. On control chest CT obtained for crepitus in the bilateral supraclavicular region and pain on anterior chest wall revealed gas density surrounding both hilar and mediastinal structures with the extension of the right supraclavicular region. This view was regarded as pneumomediastinum ten days after hospitalization ( Figure 2 ). There was no reason as a bronchoscopic procedure or trauma that can cause images in history. Piperacillin-tazobactam therapy was discontinued. TMP-SMX continued intravenously. Control CT taken 1 month later, pnönomediastinum appearance resolved completely (Figure 3) . Results: Discussion Conclusion: Most frequent causes of pneumomediastinum are barotrauma, asthma which led to increased intrathoracic pressure increase, cavitation forming pneumonia or invasive
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procedures etc. Spontaneous pneumothorax is often reported to be 35% during the PJP, however pneumomediastinum is often mentioned in the literature as rare cases. And these cases usually resolve within 1-2 weeks. If infection is considered, antibiotherapy must be started immediately and the protection of patients barotrauma are crucial. Disclosure of Interest: None declared.
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Anti-proliferative effect of natural killer subsets on hematopoietic stem and progenitor cells J. Riewaldt 1,2,* , S. Sayed 1, 3 , T. Tonn 1,2,3 1 Experimental Transfusion Medicine, German Red Cross Blood Donor Service North East, 2 Transfusion Medicine, Medical Faculty, Technical University Dresden, 3 Center for Regenerative Therapies Dresden, Dresden, Germany Introduction: Human hematopoietic stem and progenitor cells (HSPCs) reside in the bone marrow niche within a complex cellular network including mesenchymal stromal cells and various immune cells such as osteoblasts, T lymphocytes and megakaryocytes (Boulais & Frenette, 2015) . In addition, the innate immune system -with natural killer (NK) cells as one of its major components -is present in the bone marrow niche, although it is currently not clear whether and how it may contribute to HSPC homeostasis. Here, we will present data that show negative regulation of hematopoiesis by NK cell subsets in vitro. Material (or patients) and methods: Human mononuclear cells (MNCs) were isolated from either peripheral blood (for NK cell isolation), G-CSF-mobilized peripheral blood or bone marrow (for HSPC isolation) by density gradient centrifugation after obtaining informed consent of the donors. The study was approved by the local institutional review board. CD34 + HSPCs were enriched from MNCs using a magnetic activated cell sorting (MACS) approach, while different subsets of NK cells were obtained by either MACS technology or fluorescenceactivated cell sorting (FACS). HSPCs and NK cell subsets were co-cultured in vitro in semi-solid medium to assess colony forming unit capacities of HSPCs. Results: Co-cultivation of HSPCs with purified CD56 + NK cells resulted in drastically diminished colony formation after two weeks, as compared to cultivation of HSPCs alone. Although both myeloid and erythroid progenitor numbers were found to be reduced by the presence of NK cells, erythroid colonies appeared to be stronger negatively affected than myeloid colonies. Co-culturing of different NK subpopulations FACSpurified based on surface antigen expression appeared to have differential impact on HSPC differentiation/ colony formation capacity. Conclusion: Based on our data we conclude that the innate immune system contributes to control of HSPC fate and behavior by suppressing HSPCs differentiation and growth in vitro through specific NK cell subsets. Further studies to dissect specific interaction mechanisms are required. Introduction: Umbilical cord blood (UCB) is an accepted hematopoietic stem cell source for patients with hematologic diseases requiring allogeneic hematopoietic cell transplantation. To date, the majority of units transplanted have been released from public cord blood banks. Recently however, there has been interest in the use of autologous UCB to treat acquired brain injuries in paediatric patients using qualified units from both public and private/family banks, particularly in the USA. The Robertson Clinical and Translational Cell Therapy Program at Duke University commenced preclinical and clinical investigations in this setting several years ago and Smart Cells International (SCI) a UK based private bank has to date supplied 6 UCB units to the Duke programme. Material (or patients) and methods: CBUs were used to treat patients with or at risk for cerebral palsy due to hypoxic ischemic encephalopathy (n = 3), intraventricular hemorrhage (n = 1), in utero stroke (n = 1) and chronic encephalitis due to Herpes simplex virus and NMDA Receptor Antibodies (n = 1). All units were red blood cell and plasma depleted using automated Sepax TM technology prior to cryopreservation with 10% DMSO using controlled rate freezing. Total nucleated cell counts (TNCC), CD34 and viability (7-AAD) data and HLA typing results were supplied to the Duke team prior to shipment of the autologous units in monitored temperature controlled transit in vapour phase nitrogen. After premedication with acetaminophen, diphenhydramine and methylprednisolone, patients either received their total CBU as a single infusion or a portion of original product with sequential infusions according to relevant clinical trial protocol. Sequential infusions were achieved by refreezing and thawing aliquots of CBUs.
Results: At initial storage, pre-freeze mean TNCC was 555.3 x10 6 +/-329.9 (46 to 875) and mean % CD34 viability was 78.5% +/-16.4 (54 to 93.34). Following initial thawing and washing of whole CBUs by Duke, the mean recovery of TNCC was 74.5% (58 to 99.8), total cell viability by trypan blue was 94.8% (88 to 98), % CD34 was 1.1% of CD45 cells (0.41 to 3.87), CD34 cell viability assessed with 7-AAD was 42. 7% (26.39-62.95) , and 5/6 units grew CFUs. There were no infusion reactions or later adverse effects. Efficacy will be determined in companion placebo-controlled, randomized clinical trials. Conclusion: This study has yielded encouraging data as the infusions were safe with no adverse effects. Provided family banks ensure that they meet standards of practice and regulatory compliance similar to public banks, the use of privately banked CBUs therapeutically, particularly in regenerative medicine is a viable prospect for the future. Disclosure of Interest: None declared.
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Comparison of two regimens of stem cell mobilization using cyclophosphamide and G-CSF in multiple myeloma M. (40 pts.) cyclophosphamide in 77 consecutively evaluable myeloma patients (median age 59 years, range 43-69 years) who underwent stem cell mobilization in first remission. Successful mobilization chemotherapy was defined as a stem cell harvest of at least 4 million CD34 + cells per kg bodyweight. In addition, important clinical factors such as infectious complications and toxicity were analyzed for both subgroups in this study. Results: Successful stem cell mobilization was achieved in 30 out of 37 (81%) and 32 out of 40 (80%) patients, respectively. Median time to apheresis (11 vs. 12 days) and median CD34
+ content of stem cell harvest (9.1 vs. 7.6 million CD34+ cells per kg bodyweight) did not differ significantly between both groups. Importantly, there was a significant difference of ANC nadir in favor of the cyclophosphamide regimen with 2.5 g/m 2 (0.8 vs. 0.3 /nL, P = 0.01) while neutropenic fever was more often observed in patients who received 4.0 g/m 2 cyclophosphamide (16 vs. 33%, P = 0.098). Furthermore, after induction chemotherapy using bortezomib, cyclophosphamide, dexamethasone successful stem cell mobilization was achieved in 17 of 18 (94%). One mobilization failure (4.8 million CD34
+/ kg) in this subgroup was observed in a patient who had previously received adjuvant anthracyclinecontaining chemotherapy for breast cancer.
Conclusion: Cyclophosphamide at a dosage of 2.5 g/m 2 is safe and highly effective for stem cell mobilization in patients with newly diagnosed multiple myeloma in first remission after induction chemotherapy. Disclosure of Interest: None declared. ) was introduced instead. TBI and cyclophosphamide was prescribed in 7 patients. Stem cells from HLA identical siblings were mobilised with filgrastim 300ug daily for 3 days and 600ug on day 4 of the 5 day cycle. Apheresis were performed with Cobe Spectra and Optia instruments. Infection prophylaxis was with an oral quinolone, azole antibiotics and valocyclovir. GvHD prophylaxis was by immunodepletion ex vivo with alemtuzumab 1 mg for each 10 10 mononuclear cells of the graft. Patients received post-transplant cyclosporine for 90 days. Content of free alemtuzumab in the cell suspension was tested in 5 grafts by ELISA. Results: Over the study period 54 patients were entered. The diagnoses were acute leukaemia: 32 (adverse cytogenetics in 19), advanced NHL: 13, MM: 4, MDS: 5. Median age was 41 (range 6-60) years and 24 were female. The median CD34+ cell number was 4.5 (2.6-17.8) x10 6 /kg and alemtuzumab dose "in the bag" was 5 mg (2-10). Alemtuzumab was not detectable in the supernatant of the graft in any of the donor grafts. All patients engrafted. Twelve patients with consistently elevated (43.5 log value) CMV viral copies in the blood were treated with gancyclovir and none developed systemic disease. Acute GvHD (4grade 1) was seen in 7 patients and it contributed to the death in 2. Twenty patients (37%) died and at median follow up of 562 days 65% survive in remission of their malignancies. The cause of death was infection during the neutropenic period, mainly from Gram negative organisms (n = 5) or candidaemia (n = 2) and disease recurrence in 11. Conclusion: For this younger population myeloablative conditioning followed by immunodepletion with alemtuzumab was well tolerated and associated with excellent engraftment, effective control of GvHD, low CMV reactivation and low recurrence rate of the malignancy. Disclosure of Interest: None declared.
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Clinical utility of the hematopoietic precursor cells (HPC) count compared to the CD+34 cell count in peripheral blood for prediction of apheresis performance C. Introduction: The success of a bone marrow transplant depends partly on an adequate number of the infused CD34 +cells. The best time for apheresis is key. The CD34+ cell count in peripheral blood ≥ 10 x 106 / l is used as a criterion for performing apheresis. The hematopoietic precursor cells correlate with peripheral CD34+cells, is a fast alternative (90 seconds), no operator dependent, faster and less expensive (USD 9.8 ) vs CD 34+ count (US $ 110.34 ). The objective of this work was to evaluate the clinical utility of hematopoietic precursor cells count using the CD+34 cell count in peripheral blood ≥ 10 x 106 / l as a reference. Material (or patients) and methods: Evaluation of the diagnostic test in 109 determinations in 60 patients with bone marrow transplant indication in Clínica Carlos Ardila Lulle. Results: The analysis showed that the cut point of 26 HPC/ul in peripheral blood has its maximum discriminatory ability to correlate with a value of CD 34+ in peripheral blood ≥ 10 x 106 / l, with sensitivity 78.5%, specificity 85%, positive predictive value 95%, negative predictive value 95% and an area under the curve of 0.87 for correctly predicting the value of CD 34+ ≥ 10 x 106 / l in 79,8% of all the measurements. Conclusion: The determination of hematopoietic precursor cells (HPC) in peripheral blood is a useful alternative given its discriminatory capacity, fast access and reduced costs. Disclosure of Interest: None declared. Introduction: Narrative medicine is a medical approach that recognises the value of people's narratives in clinical practice, research and education. Narrative medicine aims not only to validate the experience of the patient, but also to encourage creativity and self-reflection in the health care provider and researcher. Material (or patients) and methods: In a documentary short film "Cellular immunotherapy: a Digital Story of HOPE", directed by Hedwige Daenens, we use narrative medicine to describe our procedures of cell processing and cell therapy in cancer types where relapse remains a major problem and has an important impact on survival. Rupert Suply tells his medical story and guides the audience through the different steps in making a cancer vaccine. Results: Leukapheresis, dendritic cells (DC) generation, antigen loading of DC (electroporation of Wilms' tumor 1 (WT1)-encoding mRNA), cryopreservation of WT1 mRNAelectroporated DC, timing of first vaccination, thawing of the DC vaccine, immunisation schedule, route of administration and vaccine dose are described by using documentary methods in a university hospital and research setting. Procedures in mostly restricted areas are explained in detail by qualified members of staff understandable to a general audience. The aim of this study was to establish the viability of the CD34 + cells after cryopreservation with application of propidium iodide (PI), Annexin-V and 7-aminoactinomycin-D reagent (7-AAD). Moreover we evaluated if age, disease, mobilization scheme or cryopreservation period influence the hematopoietic recovery after autologous peripheral blood stem cell transplantation (APBSCT). Material (or patients) and methods: We evaluated twenty six peripheral blood stem cell products collected from 26 patients (9 males, 17 females). The median age was 54 year (18-67). The analyzed group consists of 16 MM patients, 5 HL, 3 NHL and 1 AML. Different mobilization regimens were applied: HDCTX, HDVEP, HDAraC or intensive chemotherapy schedules (EDAP, RDHAP, BEACOPP) with G-CSF or sometimes with plerixafor. Apheresis procedures were performed with continuous flow cell separator Com.tec (Fresenius, Germany). HSC were harvested when the pre-apheresis circulating CD34 + cell count exceeds 20 cells/μL. Apheresis products contained median 11,3 x 10 6 /kg CD34 + cells. The product was commonly divided into three EVA bags (Ethinyl Vinyl Acetate). The 10% DMSO was applied as a cryoprotective agent. The programmed freezer was used before freezing in -160°C. Viability of PBSC was analyzed immediately after thawing for infusion. Viability was established according to cytometric assay protocol for propidium iodide, Annexin-V (abcam) and 7-AAD (BD stem cell enumeration kit) with BD FACSCalibur flow cytometer using BDFacsDiva software. Results: PBSC product contained median 11,3 x 10 6 /kg CD34 + cells (5, Introduction: Cord blood (CB) is an alternative source for SCT in patients with haematological diseases. Criteria for CB banking lead to a huge discard of units. The Italian CBB Network, following the original idea of P.Rebulla and coll., is promoting a multicenter study to produce CB derivedplatelet gel (CB-PG) from units not eligible for unrelated transplantation (essentially due to low TNC count) for application in diabetic ulcers repair. In future this strategy will rescue unsuitable CB to a new clinical use and reduce the discard rate favorably impacting on CBBs activity. For this reason units with TNCs o 1x10 9 and PLT4150x10 9 /l underwent a two step-procedure to prepare PLT concentrates (CB-PCs) further activated to PGs by recalcification. First, a soft spin (200gx15min) is used to obtain platelet-rich plasma (PRP), then PRP is centrifuged at 2000gx15min to pellet PLTs and adjust PCs concentration to 800-1200x10 9 PLTs/l for conservation at -80°C. As CB units may be contaminated by a variety of environmental contaminants at time of collection, sterility testing is crucial for the safety of CB-PG products. The simplest approach is to test the final product (CB-PC), volume range 5-15 mL, despite very small specimens are available for inoculating culture vials. We previously demonstrated that PPP may represent an alternative specimen, even if a percentage of false negative results was noted especially for fungi. Material (or patients) and methods: Here we evaluated the mixture of the two discarded fractions (PPP and pRBC) as alternative specimen for seeding BD BACTEC Plus culture media, namely Anaerobic/F for anaerobes and Peds /F for aerobes (recommended seeded volume 10-8 and 3-1 ml, respectively). BD media were chosen because intended for testing aerobic and anaerobic bacteria and fungi and commonly available in standard laboratories. For this purpose, we inoculated fresh CBs with low bioburden (1CFU/ml) of the following microbial isolates tested in triplicates: E. coli and S. agalactiae (aerobic bacteria), B. fragilis and P. acnes (anaerobic bacteria), C. albicans and A. niger (fungi). Then CBs were processed according to CB-PG protocol. For anerobes 8, 1 and 0.5 ml of either PPP +pRBC or PCs were inoculated into Anaerobic/F vials, while for aerobes 1 and 0.5 ml of either PPP+pRBC or PCs were inoculated into Peds/F vials; incubation time: 30 days. Results: We evaluated the adequacy of sample, inoculum volume and BD media to detect the growth of aerobic/ anaerobic microrganisms in our setting. A minimal inoculum of 0.5 mL CPs was able to detect the growth of both aerobic and anaerobic bacteria except for Propionibacterium (slow grower) whose growth was detectable by inoculating PPP +pRBC (limit volume: 1 mL). For the other strains PPP+pRBC inoculations with limit volume of 1 for aerobes and 0.5 ml for anaerobes demonstrated to be a suitable alternative sample. Conclusion: As CB-PC is a small volume product, the volume destined to quality controls is necessarily minimal. Here we demonstrated that in case of PPP+pRBC both sample and volume are adequate to detect major contaminants. A very tiny volume of PCs (0.5 mL) is also validated and is a critical step as a close system is still unavailable. Besides molecular methods able to minimize the seeding volume, our approach could be easily reproduced in contexts were such resources are not available. /kgr. Results: Engraftment was achieved in all except for one, who had reinfusion of additional cells. Neutrophil and platelet engraftment occurred at a median of +15(range 11-34d) and +30 days(range 12-62d) respectively. All but two had Donor Lymphocyte Infusions (DLI). 16 out of 17 had full donor chimerism in three months post BMT. Acute grade II-III GvHD occurred in 2 patients. Skin GvHD grade II-III appeared in 6 patients post DLI. Severe infection complications were present in 6 patients with EBV related PTLD in 4 and systemic aspergillosis in one patient. With a median follow up of 15.3 months, 9 patients are alive and well, 7 patients have died due to disease relapse and one of TRM. Conclusion: The implementation of conditioning regimens that reduce the risk of rejection, as well as the refinement of histocompatibility testing have allowed the wider performing of haploidentical HSCT. In our limited cohort of patients, the majority achieved prompt engraftment and full donor chimerism. Severe grade II-III GvHD occurred mainly post DLI and even though the incidence of moderate to severe infections was high, those were manageable in the majority of patients. Main cause of death was disease relapse or progression, as expected in this high risk group of multiply pretreated patients. Evaluation in larger cohorts, is necessary to further assess the long term benefits against the risks and to attain some insight into the immune mechanism that underlay the overcoming of HLA barrier. Disclosure of Interest: None declared. AML (n = 29), ALL (n = 9), CMML (n = 1), NHL (n = 1), cHL (n = 3); 12 patients had received a previous SCT: 10 autologous SCT, 2 URD. All patients received a MAC, 39 TBF (thiotepa, blusulfan, fludarabine), 4 TBI, fludarabine. At HSCT, 22 patients were in CR (11 in 1rst CR, 11 in 2nd or 42nd CR) while 21 presented active disease. Unmanipulated bone marrow was the stem cell source for all patients. GVHD prophylaxis was performed in all patients with PT-CY (d+3,+4 in 35 patients; d+3,+5 in 8 patients), cyclosporin from d 0, mycophenolate from d+1. Results: PMN leukocyte engraftment was reached at a median of 20 days (range 14-29). The cumulative incidence of grade II-III acute GVHD was 11.6% and moderate chronic GVHD 9%. Cumulative TRM at d+100 was 23% and the relapse rate was 20.9%. At d+30, 34 patients (79%) had full-donor chimerism. At d+90, a good immune reconstitution was present in 92% of evaluated patients. The actuarial 34 month DSF rate was 73% for patients in remission at HSCT and 18% for patients with active disease at HSCT. Causes of death were: relapse (n = 8), infections (n = 8), GVHD (n = 3), MOF (n = 2). Conclusion: Haplo-HSCT with PT-CY offers a useful treatment tool in selected patients with high-risk haematologic malignancies. In this multicentric study, we confirmed that this procedure offers long-lasting remission, with limited toxicity, a low-grade aGVHD incidence and early immune reconstitution. Introduction: Hematopoietic cell transplantation (HCT) from an haploidentical related donor is an alternative option for patients (pts) without a suitable HLA-matched related or unrelated donor, or for patients at a high-risk of disease progression. In Argentina the median time from the beginning of the search of an unrelated donor to the HCT is 5.4 months. The haplo HCT platform provides an opportunity for nearly all patients to benefit from HCT. Material (or patients) and methods: From January 2012 to June 2015, 97 pts with high-risk hematologic malignancies underwent T-cell replete haploidentical donor transplantation using post -transplant Cy (PT-Cy). Median follow-up: 6.6 months (CI 95% 4.5-8.8), Myeloablative (MAC)/reduce intensity conditioning regimen (RIC) 61 /36 pts, median age 35. 4 (5-70), female/male: 48/49. Patients underwent MAC HCT were older than RIC HCT: 30.9 vs 42.8 years-old (P = 0.001). 25.7% of the entire group received a previous transplant (MAC 18%, RIC 39%; P = 0.031), 37,1% were high-risk disease (≥3CR, PR,PD,Ref), MAC 29.5%, RIC 50%; and 62,9% standard risk (CR1, CR2), MAC 43%, RIC 18% (P = 0.052). HCT-CI: 0-2/ ≥ 3: 87.5%/ 12.5%. MAC were 39% Bu-Flu-Cy, 20% Flu-TBI, 16% Bu-Flu, 10% Flu-Cy-TBI, 16% others) and RIC regimens (55% Flu-Cy-TBI, 11%Bu-Flu, 11%Bu-Flu-Cy, 5% Flu-Mel, 18% others. In MAC group 36% were ALL, 32% AML, 6.5% CML in BC. In RIC group 42% were AML, 16.6% ALL, 16.6% HD, 16.6% NHL, 5.5% MDS, 2.7% Multiple Myeloma. Graft source in MAC group was bone marrow (BM) 45%, Peripheral blood (PB) 44.3%, BM+PB 9.8%; in RIC group: BM 27.7% PB 72.3%, (P = 0.089). GVHD prophylaxis: PT-Cy-FK-MMF MA/RIC 88.5% /80.5% and 9.8% used Cs-A instead of FK 506 in both groups. Results: Non relapse mortality (NRM) cumulative incidence (CI) at 3 and 6 moths: 15.5% and 21.8%. 66% of NRM were attributed to infections. Relapse CI at 3 and 6 months: 6.5% and 14.7%. NRM according to HCT-CI: 0-2 = 53.6% vs ≥ 3 = 17.2% (P = 0.007). One-year overall survival (OS) was 42.9%; according HCT-CI at 1 year: 0-2 = 47.1% vs ≥ 3 = 14.1% (P = 0.001). Results were not significantly different between MAC and RIC (Table) . In the multivariate analysis, only HCT-CI was associated with survival (0-2 vs ≥ 3: HR 0.25; 95% CI 0.09-0.65; P = 0.004). Introduction: Haploidentical transplantation is becoming a safe option for children needing an allograft. The development of new strategies in these past two decades improved GVHD control, outcomes and immune reconstitution. We implemented new strategies in graft engineering, CD3/CD19 and TcRαβ/ CD19 depletion, in children with malignant and non-malignant disorders. Material (or patients) and methods: Nineteen patients, median age 9 (0,5-18) years, 12 male/7 female, 7 italian/12 other countries, 16 haematological malignancies (9 AML; 4 ALL; 1 MDS; 1 LNH; 1 NB), 2 Fanconi Anemia (FA), 1 Hemofagocitic Lympho Histiocytosis (HLH), receveid haploidentical transplantation with CD3/CD19 depletion (12), TcRαβ/CD19 depletion (7) ) TcR γδ Tcells/kg in TcR αβ/CD19 depleted grafts. Several leukocyte subpopulations were analyzed in peripheral blood at days +30 ± 7, +90 ± 7, +365 ± 7 after transplantation using multiparametric flow cytometry. Results: Engraftment was registered in 17/19 patients, median 12 days (range 9-25) for neutrophil recovery, median 16 days (range 9-34) for platelet recovery and all patients had full donor chimerism at time of engraftment. Secondary graft failure developed in 2 patients (MDS and HLH). GVHD was not registered in 70% of cases. In fact, acute GVHD was registered only in 5 patients, grade 1 skin in 2 patients, and grade 1 in remaining cases. Kaplan-Meier estimate of overall survival is 65% at median follow up of 2-years. Immune reconstitution was fast: leukocyte subpopulations levels were normalized in about 365 days after transplantation. Mean values of 0.1 x 10 9 for CD3+ (+100 days), 0.2 x 10 9 for CD16+56+ (+30 days) and 0.1 x 10 9 for CD19+ (+100 days) were early reached. Conclusion: Graft manipulation by T-cell depletion is a highly effective method to prevent GVHD, improve outcome, and optimize immune reconstitution. Use of haploidentical transplantation can become a first line treatment for children who lack sibling donor, considering his safety and efficacy. Disclosure of Interest: None declared. Introduction: CD26 is an ectoenzyme with dipeptidyl peptidase 4 (DPP4) activity expressed on a variety of cell types and is known to contribute to T cell activation with well-defined modulatory effects on immune response. Evidence is mounting that CD26/DPP4 expression and enzymatic activity contribute to the emergence of autoimmune disease, immune-mediated abortions and transplant rejection. We had shown previously that, in autologous stem cell transplantation (SCT), the amount of CD26 ++ T cells contained in the autograft correlated with poor clinical outcome. In this study, CD26 ++ lymphocytes were investigated in patients who underwent first allogeneic haploidentical SCT. Material (or patients) and methods: To characterize CD26 ++ lymphocytes for future correlations with clinical outcome, especially chronic Graft versus Host Disease (cGvHD). Methods: Between January and October 2015, 10 eligible patients who underwent first allogeneic haploidentical SCT and their corresponding haploidentical donor were included in a prospective analysis. CD26 ++ lymphocytes were characterized by flow cytometry. Flow cytometric analyses were performed at defined timepoints prior to and during haploidentical transplantation. In addition, the serum concentrations and the enzymatic activity of sCD26/DPP4 were measured with commercially available enzyme-linked immunsorbent assay (ELISA) kits. ). The numbers of these cells showed substantial temporal heterogeneity after transplantation, and clinical data are currently collected to be matched with flow cytometric results and laboratory findings.
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Conclusion: CD26
++ lymphocytes define a unique set of T memory cells that have been postulated previously to possess chemoresistance and T-cell repopulating capacity. Given that Adenosine Deaminase (ADA) is anchored to T cells via CD26, the high density of CD26 is a critical prerequisite for chemoresistance, longevity and protection of a T cell population with obvious pathophysiological importance. Long-term follow up data are expected to allow the assessment of the clinical importance of this distinct subset in T-cell reconstitution, immune competence and chronic GvHD. Disclosure of Interest: None declared. Material (or patients) and methods: This is a retrospective analysis of 28 pediatric patients presented with a clinical diagnosis of stage 3 and 4 acute GVHD of the GIS who were selected from allogeneic hematopoetic stem cell transplantation (HSCT) performed. The demographics, the regimen used for conditioning and GVHD prophylaxis, clinical characteristics of GVHD including follow-up, laboratory parameters during GVHD, treatment modalities used for GVHD, response assessment in every week, complications of GVHD, and survival data were recorded.
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Results: Patient and transplant characteristics were summarized in Table 1 . Conclusion: Discussion Overall survival at 3 months after the onset of stage 3 or 4 gut GVHD was 54%. Better outcome than the adult data might be related with more usage of bone marrow as a stem cell source or different characteristics of pediatric gastrointestinal system. In general, GVHD started 14 days post-HSCT, extended to GIS GVHD in a week and progressed to high grade GIS GVHD in 10 days. The initial day of GVHD, days to extending to GIS GVHD and progressing to high grade did not influence the mortality. Melphalan and ATG usage in conditioning regimen and the drugs used in GVHD prophylaxis were not associated with survival. Low albumin level at any time of the severe GIS GVHD was associated with high mortality possibly due to more inflammatory GIS state of lost patients. Because ATG usage in the treatment of GIS GVHD significantly increased the mortality in our study, it should not be used in a routine manner. Better but not significant outcome with non-immunosuppressants seems a better treatment approach. Today best approach to GIS GVHD is to prevent and recognize it early. Treatment without immunosuppressive therapy like Photopheresis and mesenchymal stem cells seems a better approach which deserves further research with more patients. Disclosure of Interest: None declared.
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Transfusion associated graft versus host disease in a patient treated for myeloma multiplex -a case report A. Introduction: Transfusion-associated graft-vs-host-disease (TA-GVHD) is rare but usually fatal complication of transfused cellular blood components. The incidence of TA-GVHD is uncertain. Diagnosis of TA-GVHD may be difficult. This disease is characterized by fever, rasch, abdominal pain, diarrhoea, pancytopenia and liver disfunction 2-30 days after transfusion. Mortality rate is very high. Death typically occur about 51 days after the transfusion. We describe a fatal case of TA-GVHD that occurred after transfusion of blood in a patient who has been treated for multiple myeloma. Material (or patients) and methods: Case report: In a 49 year old men patient (Pt), diagnosis of Myeloma Multiplex was established in 2008. Pt received six cycles of chemotherapy (VAD) prior to autologus SCT. The maintenance therapy was applied after transplantation. One year after the transplantation relapse occured and secondary SCT had been done in pt (in decembar 2009.). Posttransplanted autologous hematopoietic reconstitution was done timely. Two weeks after transfusion in patients occur fever, nausea,vomiting and diarrhea with normal biochemistry. Infection were excluded. Twenty-three days after transfusion on physical examination noted skin rash and patechie all over the body. His respiratory, cardiovascular and central nervous system examination was normal. Laboratory data revealed pancytopenia and liver disfunction. Histology of bone marow was normal, while the histology of skin confirmed TA-GVHD. Results: After the evidence TA-GVHD was treated with pulse steroids, then the triple immunosuppressive therapy (Cyclosporin A, Mycophenolate mofetil, steroids). During treatment leads to the development of infection. Clinical application of treatment has led to a loss of fever, diarrhea and skin rash with recovery of renal function, of liver function and of blood count parameters. Six months after transfusion leads to deterioration of general condition and development of severe infectious syndromes (reactivation of cytomegalovirus, blood culture grew Pseudomonas aeriginosa), pancytopenia, heart and liver failure. The therapy is turned off CsA, continued implementation Mycophenolate mofetil and again implementation steroids. Eight months after transfusion leads to worsening TA-GVHD and death. Conclusion: The diagnosis was based on the clinical condition of the patient, fever, nausea, vomiting, diarrhea, skin rash and petechiae all over the body, kidney and liver weakness, but the diagnosis of TA-GVHD was confirmed by biopsy of the skin. The patient was treated with triple immunosuppressive therapy (Cyclosporine A, Mycophenolate mofetil, steroids), with the development of severe infectious syndrome as a complication. Lethal outcome for TA-GVHD, but patient survival was four times longer than the average. Due to its rarity, TA-GVHD requires further investigation in order to define uniform approach and develop treatment and transfusion guidelines. Disclosure of Interest: None declared.
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Development of acute graft-versus-host disease post allogeneic stem cell transplantation results in significant episodes of recurrent and prolonged hospitalisations which are with associated a significant economic burden to stem cell transplant units A. Introduction: Acute graft versus host disease (aGvHD) remains a significant cause of morbidity and mortality following allogeneic haematopoietic stem-cell transplantation (allo-SCT). Treatment options for aGvHD are limited, frequently sub-optimal and often associated with considerable sideeffects. Corticosteroids (CCS) remain first-line therapy for aGvHD, however even in those who respond (SR-GvHD) ( o50%), therapy related morbidity including fungal infections or viral reactivation is high. Patients refractory to CCS (NRGvHD) have limited subsequent treatment options and there is no clear consensus for their use. Moreover, responses are often inadequate and associated with significant complications. While the novel treatment strategies for aGvHD are costly, the indirect costs of aGvHD and the complications of current treatment strategies are less well delineated. Material (or patients) and methods: In the current economic climate with finite resources, we sought to objectively quantify the economic burden of aGvHD on our institution. We retrospectively analysed data for consecutive transplants over a 3-year period with respect to initial transplant bed stay and subsequent GvHD related re-admissions. We stratified groups by the presence or absence of aGvHD, as well as further analysing differences between SR and NR-GvHD. The costs of these differences were calculated. Results: Between January 2012 and December 2014 95 patients underwent allo-SCT within our institution from sibling (n = 43, 45%) or unrelated (n = 52, 55%) donors. The incidence of grade II-IV aGvHD was 47% (n = 45). 25 patients had SR-GvHD (27%) and 20 (21%) had NR-GvHD. In NR-GvHD patients the mean number of subsequent aGvHD treatments was 2 [range 1-4]. Development of aGvHD was associated with a significantly longer transplant admission, mean stay 36 days in patients without GvHD vs 46 days in those with SR-GvHD (P = 0.03) and S575 50 days in those with NR-aGvHD (P = 0.003). Those with aGvHD patients had significantly more re-admissions in the first year post transplant (mean 1.1 without GvHD vs 2.3 (P = 0.006) and 2 (P = 0.05) in SR and NR-GvHD respectively) resulting in longer overall inpatient days (58 vs 91 (P = 0.003) and 90 days (P = 0.001)). No differences were seen between SR and NRGvHD, which is likely to reflect the higher death rates seen with NR-GvHD as a competing risk for admission. Utilising current hospital tariffs the additional hospital stay associated with aGvHD resulted in a mean excess cost of €44,637 and €46,968 for each SR-GvHD and NR-GvHD patient respectively culminating in an average annual institution cost of €688,980 from bed stay alone. Moreover, those with NR-GvHD had significantly more episodes of CMV reactivation (0.95 episodes) compared to no GvHD (0.32) (P = 0.01) or SR-GvHD (0.4) (P = 0.01). This is likely to further increase the economic burden of NR-GvHD and further cost analysis including antiviral, antifungal and diagnostic costs is underway. Conclusion: The additional cost burden of aGvHD is significant for the transplant community. Strategies for steroid reduction to achieve reduced hospital inpatient stays are crucial for patient morbidity and to achieve institutional financial stability. Additionally these data highlight the need for improved strategies in NR-GvHD. Disclosure of Interest: None declared.
AB31
The role of prolonged ECP therapy İn bronchiolitis oblİterans after allo-hsct Introduction: Chronic GVHD (cHVHD) continues to be a major complication after allo SCT. The lung involvement and development of bronchiolithis obliterans (BO) are particularly serious and life threathining conditions. Despite the advanced medical and cellular therapy the mortality and morbity are still high. Extracorporeal photopheresis treatment revealed a significant improvement of skin cGVHD, and several studies indicated steroid sparing effect on cGVHD in general. Howeover the effect of ECP on lung function in patients with BO after HSC and lung transplantation is controversial. Selective downregulation of T-cell-mediated immunity is thought to explain the effect of extracorporeal photopheresis in the treatment of GvHD. Material (or patients) and methods: We report a case of extensive cGVHD (skin+lung) in 17 years old girl affected by B-ALL who received unmanipulated bone marrow transplant in the 2nd remission of disesase from her HLA = ABO# brother. Full donor engrafment was documented on day +21. She developed grade II-III acute skin cGVHD responded to steroid therapy (metihylprednisolon 2 mg/kg). She was discharged on day +41. Subsequently she has had several admittions to the hospital due to severe hemorrhagic cystitis. 10 months after transplant she developed extensive sclerodermiform skin cGVHD. The patient refused the steroid therapy, thus the PUVA therapy was given for 6 months. There was a significant response, except the permanence of lichenoid lesions localized on both ankles. The immunosupressive therapy (IS) has been gradualy reduced and stopped. Six months later she presented with dry cough and dispnea; wheezing and inspiratory squeaks were present on thoracic examination in absence of infection. Based on HRCT of the chest and PFT the diagnosis of BO was made. The next 6 months the symptoms, RFT and radiologic findings (HRCT) impaired despite the aggressive immunosuppressive therapy. Long course of ECP program has been added to the IS therapy. Results: She has performed 3 courses of ECP therapy. At the end of the second course of ECP therapy, cessation of disease progression was observed. She has completed 18 months of ECP therapy. Clinical symptoms have disappeared, PFT and HRCT of chest have drammaticaly improved.
Conclusion:
The effect of ECP in the treatment of cGVHD may be correlated to the duration of therapy. A prolonged ECP therapy should be considered as a therapeutic option in the treatment of BO after allojeneic HSCT. Introduction: Extracorporeal photopheresis (ECP) is an effective cell therapy in graft-versus-host disease (GVHD) after bone marrow transplantation, which requires an optimal mononuclear cells (MNC) collection through apheresis devices for further manipulation.The end of this study was to compare the semiautomatic COBE Spectra (Terumo BCT ® ) and the new automated Spectra OPTIA (Terumo BCT ® ) in terms of efficacy and safety in ECP. Material (or patients) and methods: All patients with refractory acute and chronic GVHD in treatment with ECP were retrospective studied, from June 2014 to May 2015. Patients were alternatively assigned with either apheresis device. Peripheral blood sample was removed to the patients before and after each leukocyte apheresis (LA) procedure and also had a sample of each product just before reinfused. We perform the cell blood count (CBC) in Unicell DHX800 (Beckman Coulter ® ) in all samples. Collection efficiency (CE) of white blood cell (WBC) and total mononuclear cells (TMNC) and platelet loss(PL)were calculated as: WBC CE% = [product WBC-NCx10 6 /mL x product volume mL/ preapheresis NC (x10 6 /mL)x(Vol processed Ml-AC volume Ml)] x100 TMNC CE% = [product MNCx10 6 /mL x product volume mL/ preapheresis MNC (x10 6 /mL)x (vol processed mL-ACvolume mL)]x100 PL = [Preapheresis count-Postapheresis count/ Preapheresis count]x100 *In all cases it was complete with saline solution to a total volume of 300 ml. It were compared patient's CBC before and after the LA, the CBC of the product and the procedure variables with both devices, using non-parametric methods (U Mann-Whitney). Results: A total of 200 procedures (100 performed in COBE and 100 in OPTIA) were included, carried out in 11 patients (8 with chronic GVHD and 3 with acute GVHD). Central venous access was required in 10/11(90.9%) patients. CBC results before and after LA were similar. In OPTIA group, the processed volume, the volume of the product, the percentage of loss of platelets, the amount of ACD used and the amount of ACD in the product, were significantly lower. The hemoglobin and the hematocrit were higher in the OPTIA group, and TMNC count was similar with both devices. Notably, TMNC CE was greatest in the OPTIA group.There were no differences in the duration of the procedure. Details are shown in Table 1 . The procedures were well tolerated with both devices, and only mild episodes of hypocalcemia were recorded in four procedures (two in OPTIA group, and two in COPE group). Conclusion: In our study, the Spectra OPTIA proved very effective and save in collecting MNC for ECP in GVHD.Because of this, we could consider shortening the time of collection with this device. The lower PL is very important because these patients often have low platelet counts. It also provides the advantage of being automatic and lower use of ACD what may reduce the hypocalcemia risk. The hemoglobin and the hematocrit were higher in the OPTIA group, but in the established limits for proper irradiation. Introduction: Transplant-associated thrombotic microangiopathy (TA-TMA) represents a challenging and potential lifethreatening complication after alloHSCT. This syndrome occurs approximately in 10% to 20% of patients after alloHSCTs, 1 and it is characterized by inflammation, thrombotic microangiopathy, hemolytic anemia, thrombocytopenia, and evidence of organ damage, particularly renal and neurological involvement. The mortality rate is approximately 30-80%. The treatment is problematic and no generally effective therapies are available. Therapeutic options consist in a wide range of treatment such as Plasma exchange (PEX) or immunosuppressive drugs, however lacking in high response rate due to the unclear TA-TMA pathophysiology. Recent data suggest that endothelial injury and complement activation could be involved in the pathogenesis of TA-TMA. Eculizumab, a monoclonal antibody against terminal complement, may be an innovative and effective therapeutic option for TA-TMA. Material (or patients) and methods: We report a case of TA-TMA in a recipient of alloHSCT for acute lymphoblastic leukemia B Ph negative. 34-year old male who underwent alloHSCT from unrelated donor 9/10 HLA compatible with total nucleated cells 10.54x10 Conditioning regimen consisted of TBI 1200 cGy and Cyclophosphamide 60 mg/Kg on days -3, -2. Anti Thymocyte Globulin, Methotrexate and Ciclosporine (CsA) were given for Graft versus Host Disease (GvHD) prophylaxis. Results: At day +23 of reinfusion the patient experienced cutaneous acute GvHD (skin 2, global 1) treated with prednisolone 2 mg/Kg. At day +30, due to worsening of cutaneous rash and liver dysfunction (elevated transaminase and bilirubin levels), the patient started treatment with Etanercept 25 mg/sc for a total of 3 infusions. Meanwhile the LDH level was increased up to 1024 U/L and was associated to anemia, trombocytopenia and renal deterioration; schistocytes were detected at the peripheral blood smear (10 HPF) and urinanalysis revealed a protein concentration of 8.052 mg/ 24 h. CSA was replaced with mycophenolate mofetil and the patient started treatment with plasma and PEX daily, stopped after 4 cycles due to trombocytopenia. Few days later patient developed peripheral paresthesia and hypostenia; cranial MRI was performed, with no pathological features. Despite recovering renal status and hb level, C3 and C4 levels were inferior to normal range and patient started treatment with Eculizumab 900 mgs for a total of 2 infusions. After the first dose of Eculizumab there was a marked improvement of performance status, LDH, hb level and platelet count (Fig. 1) ; schistocytes in the peripheral blood decreased until disappearance. At +113 diarrhea gr3 appeared and a colonoscopy showed ulcerative mucositis and inflammatory infiltrates. Patient received Infliximab 600 mg/mq (4 doses). Actually patient is at +200 and experience only mild cGvHD (NIH scale: mouth 1, eyes 1). Conclusion: This report support the potential effective activity of Eculizumab in the treatment of life-threatening TA-TMA even when it is associated with refractory acute GvHD. References: 1. Chapin J, Shore T, Forsberg P et al. Introduction: We have been using at our institution phototherapy -PUVA and UVBNB as skin direct therapy associated to ECP to treat different manifestations of cutaneous GVHD for the last 24 years. ECP is indicated to patients not responsive to steroids, those with IS toxicity or those who need early withdrawal of IS. Material (or patients) and methods: All patients treated with phototherapy since 1990 were prospectively evaluated in a single center institution. PUVA and UVBNB was performed with standard machine and UVA initial dose was based on skin type. ECP was performed with UVAR ® photophresis system and liquid psoralen. PUVA and UVB-NB could also be combined with ECP for different clinical cutaneous manifestations or as ECP maintenance therapy. Complete response (CR) was defined as more than 75% of clinical response and partial response (PR) between 50% and 75%. Patients who had less than 30 phototherapy sessions were considered early for evaluation (EA). Results: Puvatherapy was used in 67 patients to treat lichen planus like and sclerodermic chronic GVHD with no visceral involvement. UVBNB was used in 25 patients for vitiligo, limited lichen planus like chronic GVHD, follicular keratosis, patients with psoralen oral intolerance and children. ECP was reserved to treat 43 patients with extensive sclerodermic, fasciitis cGVHD, systemic cGVHD and 13 patients with acute GVHD corticosteroid-refractory. Patients treated with ECP had more severe cGVHD (P o0,01). ECP was combined with PUVA in six patients and in UVBNB in 13. Conclusion: PUVA and UVBNB are topical direct therapies and should be considered in patients in whom long-term systemic IS is antecipated. Phototherapy as topical therapy on the skin associated with ECP helps in the treatment of sclerotic cGVHD extensive and vitiligo that are often seen in the same patient. This study shows encouraging results and suggests that phototherapy treatment results in more rapid reduction of immunosuppression. Introduction: Chronic graft versus host disease (cGvHD) is major predictor of long term survival after allogeneic stem cell transplantation (HSCT). Similarities with autoimmune diseases are due to B lymphocyte (B-Ly) dysregulation and thus abnormal production of various auto antibodies (Ab). Using of chimeric monoclonal anti CD20 antibody (Rituximab) is based on their "in vivo depletion" of B-Ly and thus we estimate efficacy and safety of Rituximab in the therapy of refractory severe cGvHD. Material (or patients) and methods: Seven patients, M/F 5/2, have received Rituximab after failure to standard treatment (Methylprednisolone, Cyclosporine A, Mycophenolate mofetil, Azathioprim, PUVA…). Median age was 29 years (18-49). All of them have received HLA identical sibling transplant with stem cells from peripheral blood in 5 and bone marrow in 2 cases. Despite standard prophylaxis, 4 of them had acute GvHD
S578 grade 1-2 and all of them had severe cGvHD with lichenoid, sclerodermic or pemphigoid skin feature, buccal mucosa involvement with sicca syndrome. Extracutaneous manifestation included lung in 4, liver in 4 and thrombocytopenia in 3 cases. One patient had CMV infection prior to exacerbation of cGvHD. We applied Rituximab in usually recommended regimen (375 mg/m 2 weekly for 4 weeks). Results: Exact responses were measured with Schirmer test, spirometry, liver function parameters and hematological findings. Good effect was observed in 5 patients (71,4%) even after first application. Best results were achieved concerning mucosa (significant reducing of sicca syndrome) and skin (improvement of turgor, lichenoid changes and pemphigoid reconstitution). Lung and liver function were improved as well, but it should be mentioned that other immunosuppressant were also given (particularly Mycophenolate mofetil and Azathioprim). Three patients had severe infectious complication, two of them have died from sepsis, and one of them have developed abscesses pulmonalis in fourth week of treatment. Conclusion: Results from our modest data suggests that monoclonal anti CD20 antibody in the treatment of severe refractory cGvHD is encouraging but needs further investigation. Disclosure of Interest: None declared. Introduction: Human herpesviruses (HHVs) are commonly found in general population but also in patients after allogeneic hematopoietic stem cell transplantation (HSCT) where they may cause severe complications. Particularly, cytomegalovirus (CMV) infection was significantly more frequent among adults and was associated with a higher risk of developing acute graft-versus-host disease (aGvHD) (1) (2) (3) . Therefore, the aim of our study was to determine prevalence of particular HHVs in patients with oral chronic graft-versus-host disease (cGvHD) and possible role in these patients. Material (or patients) and methods: This pilot study enrolled 36 cGvHD patients who are part of a larger multidisciplinary cGvHD project at the University Hospital Center Zagreb, Croatia. Patients were evaluated for clinical and cGvHD characteristics; severity of cGvHD and oral involvement were determined by using established NIH Consensus criteria. Cytobrush swabs from oral mucosa were collected from all patients. Specimens were analyzed by specific polymerase chain reaction (PCR) of several HHVs (CMV, Epstein-Barr virus -EBV, herpes simplex virus 1 and 2, and varicella zoster virus -VZV). Data were evaluated descriptively and Chi-square test was used to calculate statistical significance. Results: 36 cGVHD patient were enrolled, of which 18 men (average age 37.8) and 18 women (average age 40.9).Twenty patients had diagnostic signs of oral cGvHD (55.6%), 13 were (36.1%) without, and 3 (8.3%) had distinctive signs of oral cGvHD. Overall, in 18 of 36 patients (50%) no HHVs were identified, 3/36 (8.33%) had CMV, 13/36 (36.11%) had EBV, 2/33 (6.06%) VZV and no HSV 1 and 2 were found, respectively. EBV was statistically significantly found more often than the second most common CMV (P = 0.0046). There was no statistically significant difference in HHVs between patients with and those without oral cGvHD.
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Conclusion:
Although proportion of patients with cGvHD, especially patients with oral cGvHD was EBV positive, indicating the possibility that EBV is more common in chronic GVHD, further studies with control groups are necessary to determine the role of EBV in cGVHD. Our preliminary data also indicate that the use of molecular methods to determine the presence of HHVs is valuable method in the follow-up of cGvHD patient particularly by using oral cytobrush specimens for PCR analysis as less invasive alternative method for monitoring these patients. Introduction: Bleeding complications and Graft-versus-Host Disease (GVHD) are severe complications in hematooncological patients and patients undergoing allogeneic transplantation (HSCT). A systematic and prospective assessment of these complications is essential in order to evaluate therapeutic interventions, optimize patient care and thus improve patient outcome. Different bleeding scores to be used in clinical practice but also for research purposes have been developed, including the WHO and BSMS scores. 1, 2 Recently, the National Institute of Health (NIH) updated their recommendations for diagnosis and staging of GVHD. 3 For the prospective and systematic evaluation of bleeding complications and GVHD, we developed an electronic tool with the aim to improve patient care and for clinical research purposes. Material (or patients) and methods: In collaboration with IT-specialists we developed a browser based electronic tool for assessment of bleeding and GVHD according to the published guidelines. This tool (bleedHD) works on different devices and thus allows efficient bedside assessment. Collected data include patient's and disease characteristics, type of intervention, type and site of bleeding as well as GVHD features, according to the published guidelines. Results: bleedHD is a secured browser based, user-friendly tool and was improved over time and validated on a large number of patients. The current available tool allows easy collection of patient characteristics including names, date of birth, gender, age, diagnosis and interventions (type of transplantation and stem cell source). Thereafter, the assessor can choose between assessment of bleeding (either WHO or BSMS or both) or GVHD or both. According to the published NIH guidelines, GVHD can be scored in case of first diagnosis, by every single organ (organ scoring), by activity assessment and finally by self-reporting by the patient himself. The user will be guided step-by-step through the different scoring systems. Assessments can be interrupted at any time and resumed later. bleedHD automatically gives an overview over time and scores S579 of each patient. During assessment, explanations, additional information and pictures can be retrieved allowing correct assessment also for not experienced users. All the data are safely stored on an appropriate server. Complete data can be exported as CVS file for further analysis and research purposes. In our experience bleedHD significantly improves the accuracy of bleeding and GVHD assessment in an easy, fast and straightforward approach. Scoring patients became much more convenient and easy. Additionally it allows a prospective bedside assessment and clear demonstration of clinical changes in case of therapeutic interventions. Physicians and nurses from other institutions, which are involved in patient care can have access to bleedHD and also assess GVHD during follow-up. Conclusion: bleedHD is an innovative and easy tool for an accurate, efficient and prospective assessment of bleeding complications and GVHD in hemato-oncological patients. This can improve patient care and outcome. Additionally, it can be a useful tool for clinical research in the therapy of GVHD and to further investigate the efficacy of platelet transfusions or other interventions in thrombocytopenic patients. Introduction: Graft versus host disease (GVHD) is a lifethreatening complication of allogenic hematopoietic stem cell transplantation, which has a wide range of pleomorphic manifestations at multiple organs. Extracorporeal photopheresis (ECP) is an immunomodulatory therapy that provides encouraging results in skin GVHD but also in multiorganic involvement (skin, gut and liver). The ECP reverses GVHD through the reduction in response of donor effector T cells and production of donor Tregs. Material (or patients) and methods: We retrospectively analyzed 24 patients with refractory acute and chronic GVHD treated in our center with ECP from September 2009 to October 2015. The median age was 16 (range 2-61), the main primary disease was acute myeloid leukemia. There were 12 patients with aGVHD that were classified according to the degree of severity in grade II and III 67% and grade IV 33%, 12 patients with cGHVD patients were classified according the global scoring of NIH consensus into moderate 75% and severe 25%. Skin was the organ mostly involved (79%), while 37% of patients had multiorgan involvement. ECP was performed using the online system THERAKOS, and the off line system using the Spectra Optia separator, and the UVA device MACOPHARMA. Patients with aGVHD received 2-3 consecutive days of ECP at weekly intervals until response and then tapered to every 2 to 4 weeks, patients with cGVHD received 2 consecutive sessions at 2 week intervals. Results: The Overall response rate (ORR) for aGVHD and cGVHD was 75% and 91% respectively. The ORR for patients with aGVHD grade II-III was 100% and grade IV was 25%. In moderate and severe cGVHD the ORR was 66 and 100% respectively. We analyzed organ specific complete response (CR) rates in patients with aGVHD and cGVHD (graphic 1), in skin involvement CR was achieved in 78% and 72% (aGVHD and cGVHD), in multiorganic involvement (skin, liver and gut) the CR was 50% and 67% respectively. Seven patients died, the main cause of death was infectious disease. The procedure was well tolerated, only NCI grade I adverse events were observed.
In our experience the use of ECP for aGVHD, had favorable rates of response especially at early stages. There is tendency for higher responses in aGVHD with cutaneous involvement. We observed significant rates of responses in moderate and severe cGVHD. We found that ECP has a considerable activity against multiorganic cGVHD. The early intervention with ECP improves the poor outcome of patients with steroid refractory GVHD. Introduction: After autologous hematopoietic stem cell transplantation (HSCT) it exists a period of time with an increased risk of infectious diseases because of immune dysfunction. For this reason, it is advisable to administer several vaccines beginning 6-12 months after transplantation. In our hospital, the haematologist responsible for posttransplant monitoring establishes the prescription of vaccination, both the dates and the number of doses, including vaccines against Stp. Pneumoniae, H. inluenzae type b, C. tetani, C. diphtheria, Poliovirus and Influenzavirus. After this, patients are sent to the Primary Care Trust (PCT) where the general practitioner is responsible for the correct completion of the set prescription, indicating the administration to the nursing unit. Material (or patients) and methods: The aims of the current study are: a) to assess treatment adherence to the vaccination schedule elaborated in our unit and determine reasons for lacking of adherence, if this is the case; b) to identify administrative problems (lack of vaccines, absence of collaboration between the general practitioner and the haematologist responsible, etc.); c) to describe adverse reactions related to vaccines (fever, rash, etc. Introduction: It has been reported that reactivation of hepatitis B virus (HBV) could be fatal in patients with malignancy following systemic immunosuppressive chemotherapy, especially combined with rituximab, or hematopoietic cell transplantation (HCT). Many guidelines regarding HBV reactivation following chemotherapy recommends that HB surface antigen (HBsAg), antibody to HB core antibody (anti-HBc), and antibody to HB surface antibody (anti-HBs) should be tested before the chemotherapy is initiated. Japanese guideline for HBV infection in whom received chemotherapy was published in 2009; however it remains a few cases reported who developed fulminant hepatitis from HBV reactivation following chemotherapy. This fact implies that the guideline is not properly observed. Therefore we conducted this study to evaluate whether HBV screening tests before HCT were employed according to the guideline in the HBV-endemic region of Japan. Material (or patients) and methods: We retrospectively analyzed 127 patients who were treated with allo-or auto-HCT between 2006 and 2014 at Kansai Medical University Hospital. Results: A total of 127 patients were studied. 43 patients underwent allo-HCT and 84 patients underwent auto-HCT. All patients were examined on HBsAg before the HCT. 2 patients (1.5%) were proved to be HBsAg positive carrier, who received nucleoside analog against HBV thereafter. Only 5 patients (3.9%) were investigated neither on HBcAb or HBsAb. Although 25 patients (19.6%) were seropositive either for HBcAb or HBsAb, 19 patients (76%) among them were not examined on HBV-DNA as follow-up. Fortunately no fulminant hepatitis was experienced, 2 patients developed late-onset reactivation. These 2 were patients who underwent auto-HCT. One was a HBV carrier who had received prophylactic nucleoside analog during the whole course of therapy, whose HBV-DNA level resulted in undetected. She developed reactivation of HBV with long interval after auto-HCT. The other had occult infection of HBV, who converted to late-onset reactivation after auto-HCT. Neither of them developed hepatitis after they were retreated with nucleoside analog against HBV. Conclusion: Improvement was achieved by the guideline on management against HBV reactivation following chemotherapy. While it did not pervade perfectly even in the HBVendemic region of Japan. Most hematologists would recognize how important to examine the HBV serostatus before the HCT; however they are afraid to lose the following blood test regarding HBV. The guideline might be complicated to observe the follow-up study from the point of view. Thus, the guideline is preferable to be simplified and the institutional surveillance should be established to encourage the follow-up study. If other medical staff composed of nurses, pharmacologists, and laboratory technicians as well as hematologists, is aware of HBV serostatus of the patient during the entire course of chemotherapy, it could be attributable to prevent from missing the follow-up study. Introduction: Citomegalovirus meningoencephalitis is a rare and fatal complication after allogeneic hematopoietic transplantation. We describe a paediatric patient who developed the infection one year after cord blood transplantation although preemptive treatment and good control of blood viremia. Material (or patients) and methods: A 15-year-old male patient with Ph+ acute lymphoblastic leukemia in third complete remission received an unrelated 5/6 HLA matched single umbilical cord blood transplant. The patient and the donor (maternal IgG serostatus) were CMV-seropositive. The conditioning regimen was based on fludarabine, thiotepa, busulfan and anti-thymocyte globulin. Cyclosporine and a short course (14 days) of prednisone were given as GVHD prophylaxis. Because of acute grade II GVHD (gut) patient received two courses of prednisone 2 mg/Kg/day and oral budesonide starting on day +7 and +105, respectively. Cyclosporine discontinuation started on day +205. Intravenous Ig was administered monthly. The patient showed good engraftment and total donor chimerism although with a poor immune reconstitution (persistent low CD4 count) implying frequent CMV asymptomatic viremia. Complete molecular remission was maintained.
Results: On day +300 the patient started with apathy, memory lost, language deficit and lethargy. Brain magnetic resonance imaging showed signs compatible with meningitis.
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Cytomegalovirus was detected by quantitative PCR technique in the cerebrospinal fluid (CSF) (23.000 UI/ml) whereas it was negative in blood. An autoimmune cause was ruled out. At that moment the patient was receiving oral valganciclovir as preemptive treatment for a previous CMV viremia (maximum 3.400 UI/ml Introduction: Fatal infection by bacteria and invasive fungal (especially Aspergillus) is the most frequent cause of severe aplastic anemia (SAA) mortality. However, there are very few spesific reports about infections and their therapy in patients with AA. We aimed to discuss the therapy scenarios for two SAA patients who have invasive fungal infection. Material (or patients) and methods: Case 1. A 26 year-old male patient with SAA was admitted with fever, periorbital swelling, periorbital pain, and bloody nasal discharge. The patient had been diagnosed with SAA. Computed tomography of the paranasal sinuses demonstrated a space-occupying lesion in the right maxillary and ethmoid sinus region. Histopathologic examination revealed numerous PAS-stained Aspergillus hyphae without tissue invasion. Tissue culture revealed Aspergillus fumigatus. Voriconazole administration was started. Case 2. A 24-year-old male patient was admitted to our clinic due to pancytopenia. The patient was diagnosed with SAA and allogeneic HSCT was planned. However he had fever on day 3 of admission. Invasive pulmonary aspergillosis was suggested based on the presence of pneumonic consolidations on CT of the thorax and galactomannan positivity (1.18 index). Liposomal amphotericin B was started in therapeutical dose. Results: Invasive fungal infections (IFI), particularly those caused by Aspergillus species, have long been recognised as a major cause of death in SAA. Mortality rate is still high in SAA patients with IFI despite antifungal therapy and even granulocyte infusion plus G-CSF administration. A condition in which the response to immunosupressive therapy can take up to 6 months to develop leading to a neutropenic period that is typically longer than that seen after HSCT. HSCT with active IFI places the patient at a higher risk for transplant related mortality. However, HSCT without delay is only curative treatment approach in some patients. We performed HSCT under antifungal therapy in both patients. Both patients overcame the neutropenic period and they were discharged without severe morbidity. Conclusion: We conclude that an immediate HSCT may be life-saving and G-CSF plus granulocyte transfusion may be used as a bridge to HSCT in patients who do not satisfactorily respond to antifungal therapy although there are scarce data about the HSCT in SAA patients with active invasive fungal infection.
R- Incidence of febrile neutropenia episodes (49(66%) in posaconazole vs22(68%) in fluconazole; P = 0,79) and invasive fungal infections (3(4%)in posaconazole vs 1(3%) in fluconazole; P = 0,81) were comparable for both antifungal agents. However, patients receiving posaconazole had a lower incidence of empiric/preemptive antifungal therapy (10(20%)vs11(50%); Po0,01) which associated with a higher probability of systemic antifungal treatment free time (21% vs 57% at 100 day; Po0,01). The median days of antifungal treatment were 12(3-30) in posaconazole and 10(1-29) in fluconazole group (P = 0,19). No difference was observed in terms of 1yTRM (28% in posaconazole and 36% in fluconazole; Po0,99) and 1yOS (58% in posaconazole vs55% in fluconazole; Po0,77). No adverse serious events occurred during the antifungal prophylaxis. Fifteen patients (20%) treated with posaconazole temporarly withdrawn the drug because of gastrointestinal symptoms. Conclusion: Our experience suggests that antifungal prophylaxis with posaconazole is well tolerated and may lead to a lower rate of empiric/pre-emptive antifungal therapy and a higher probability of systemic antifungal treatment free time period for patients in the early neutropenic phase post allogeneic HSCT. Disclosure of Interest: None declared. Introduction: Changes to the oral cavity in the transplant setting can be caused by numerous factors including the disease, the direct and indirect impact of treatments, coexisting co-morbidities and underlying oral health problems. Material (or patients) and methods: The United Kingdom Oral Mucositis in Cancer Care (UKOMiC), a multi-professional expert group was founded in 2011 to address the challenges of oral complications secondary to disease and treatment in the transplant, cancer and supportive care setting. The first edition of the oral care clinical guidance produced in 2012 has been widely used within transplant centres in the United Kingdom and many other countries to help support and improve practice. The group has continued to disseminate the guidance, through the delivery of several national study days, numerous educational workshops and lectures, while continuing to collaborate with international organisations.
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Table1. Engraftment and results
Posaconazole
Results: This presentation focuses on the recently updated oral care guidance which is based on the most recent evidence, clinician feedback and expert opinion.The guidance continues to focus on the key principles of; an accurate assessment of the oral cavity, identification of risk factors, regular care, earlier intervention to prevent/reduce oral damage and the correct treatment interventions. Conclusion: It is anticipated that this updated guidance will further assist health care professionals in planning and implementing oral care into everyday practice, thus reducing a significant health burden for the patient and reduce demands on limited health care resources. Disclosure of Interest: None declared. . Concern about fertility negatively affects the quality of life of the patients which frequently ask about the optimal time to address these issues and the ways to do it. A few cases of successful pregnancies after autologous or allogeneic transplants, have been recently reported but, to our knowledge, none after cord blood transplantation (CBT). We report the case of a young woman who successfully carried out a pregnancy with a donated oocyte, 7 years after a TBI-including myeloablative CBT. Material (or patients) and methods: Our patient, a 27-year old woman, was diagnosed of pro-B acute lymphoblastic leukaemia in August 2006. She was treated with a national high-risk ALL protocol (PETHEMA HR-ALL 2003), with persistence of disease after induction. First complete remission was achieved after the fourth consolidation. An allogeneic CBT was performed in March 2007. The CB unit was co-infused with haploidentical selected CD34+ SC from an unrelated donor. Conditioning was myeloablative and included fractionated TBI (total dose 1000 cGy), fludarabine 120 mg/m 2 (30 mg/m2, days -5 to -2), cyclophosphamide 120 mg/kg (60 mg/kg, days -4 and -3) and thymoglobulin 4 mg/kg (2 mg/kg, days -2 and -1). After CBT, the patient has remained in complete remission with a normal performance status. The patient consulted because she had been trying unsuccessfully to conceive. She was amenorrheic. A complete hormonal evaluation was performed to confirm that thyroid function was preserved and prolactin levels were normal. After evaluation, a procedure of in vitro fertilization (IVF) of a donated oocyte using the patient's husband sperm was proposed. Two embryos were transferred to the uterus of our patient. Results: A single pregnancy ensued which was carried out till term with no complications. The baby, a healthy 3500 g girl, was born at week 40+5 after a cesarean section. Ten months later, both mother and child remain in good health. Conclusion: Reproductive issues in young women who undergo myeloablative allogeneic SCT are especially difficult to address and solve. Physicians must improve their practices, provide information and educational materials and facilitate the physician-patient discussion on fertility preservation. Guidelines with recommendations are available for health-care providers 3 . These recommendations are based on best available evidence. Successful pregnancies in this population have to be reported. To our knowledge, this is the first report showing a successful pregnancy and delivery after myeloablative cord blood allogeneic transplantation. Kidneys malfunction started from D+43 (high azotemia) followed by PLT level decreasing. First macrohematuria episode was revealed on D+56 (HB level de-greased to 5,6 g/dL). CMV-viremia was also revealed. Due to revealed thrombocytopenia, LDH increasing to 2076 U/l, decreasing of HPT level, sever azotemia, negative Coomb's test, ADAMTS 13 serum level 60%, factor H Ab -66%, C3-compl 107 mg/dL, C4-compl -17,8 mg/dL TA-TMA-HUS was revealed. 15 y.o. boy suffered ALL from 2003 received Allo-HSCT in 3rd remission from MUD in 2013. Due to relapse, repeated haplo-HSCT was performed in 2015 (in CR). Conditioning: TBI 4 Gy, BU, Flu, Timo. GvHD prophylaxis: CPH on D +3, +4, CsA/sirolimus. Patient engrafted on D+27. GvHD skin gr. III. Renal malfunction started from D+43 (high azotemia) followed by PLT level decreasing. First macrohematuria episode was revealed on D+56 (HB level decreased to 5,6 g/dL). Due to thrombocytopenia, LDH increasing to 2076 U/l, decreasing of HPT level, sever azotemia, negative Coomb's test, ADAMTS 13 serum level 60%, factor H Ab -66%, C3-compl 107 mg/dL, C4-compl -17,8 mg/dL TA-TMA-HUS was revealed. Results: Patient was treated with defibrotide, DEXA/PRED and fresh frozen plasma with positive dy-namic -decreasing of LDH, increasing of PLT and normalization of azotemia. Macrohematu-ria solved. Second episode of TA-TMA-HUS started from D+ 93 with fast decreasing of HB to 6,1 g/dL, LDH increasing to 1361 U/l, progressed azotemia and hypofunction. Previous therapy (including IVIGs) was ineffective. Despite of absence of CD20+ cells in blood, Rituximab was infused at D+124 and D+130 (375 mg/sq.m. Among the 41 patients who developed late-onset HC, BKV was the most common viral agent identified. HC developed in 12.8% of the patients treated with myeloablative conditioning and in 10.5% of the remaining patients (P = 0.704). Of the 197 patients with acute GVHD, 35 (17.8%) developed HC and only 7 (4.9%) showed HC in the absence of GVHD (Po 0.001). HC was also more frequent in males than females (P = 0.027). The median survival was 5.2 years (95% CI: 3.6-6.8 years) in the group of patients who presented HC and 6.7 years (95% CI: 5.9-7.5 years) in patients who did not (P40,5).
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Conclusion:
The incidence of HC in our series of patients was similar to that found in other studies. In our cohort of patients being male and having acute GVHD was a risk factor to develop HC. Introduction: The hematopoietic reconstruction with allogeneic bone marrow is an established method of treatment for a variety of haematological, oncologic and immunologic diseases. HSCT is associated with considerable morbimortality due to factors like recurrence of underlying disease, HLA compatibility between donor and recipient and type conditioning regime. This study investigated the association between human neutrophil alloantigens (HNA) and engraftment, the occurrence of acute GVHD and transplant related mortality in patients who underwent allogeneic hematopoietic stem cell transplantation at our center. Material (or patients) and methods: In a prospective cohort study carried out at Hospital de Clínicas de Porto Alegre we evaluated 28 patients transplanted between May of 2013 and April of 2014 and their respective donors. HNA typing was performed by PCR-SSP and antiHNA antibodies were detected using the LABSCREEN MULTI kit (LSMUTR-One Lambda). Results: The age ranged from 1 to 63 years, with an average of 20.4 ± 17.5 years. Nineteen were pediatric patients ( o21 years) with an average age of 10.05 ± 6.4 years, and among adult patients the average was 42.2 ± 12.6 years. There was a discreet male prevalence, 16 (57,1%). The acute leukemias were frequent in 19 (67.95%) of patients, other malignant oncohematological diseases (Hodgkin Lymphoma and nonHodgkin's Lymphoma) in 3 (10.7%) and non-malignant (myelodysplastic syndrome, osteopetrosis, paroxysmal nocturnal hemoglobinuria, aplasia and granulomatous disease) in 6 (21.4%). 19 of the patients (67.9%), had the disease for less than 12 months at the time of the transplant and 25 (89.3%) were fully HLA compatible with their donors. Myeloablative conditioning regimen was used in 16 (57.1%) of the patients and the standard prophylaxis for GVHD (cyclosporine and methotrexate) was used in 15 (53.6%) of the patients. The engraftment occurred at a median of 19 days. Four patients (14.3) died before the engraftment. Approximately 61% (17 patients) showed acute GVHD (in all stages) and the rate of related mortality (TRM) was approximately 43% (12 patients). Patients who received HSCT from a related donor had TRM of approximately 41% (7 patients) and those who have received from unrelated donor had approximately 45% (5 patients). The frequency of HNA antigens detected in donors was 46,4% HNA-1a, 89,3% HNA-1b, 3,6% HNA-1c, 96,4% HNA-3a, 32,1% HNA-3b, 96,4% HNA-4a, 21,4% HNA-4b, 85,7% HNA-5a and 71,4% HNA-5b. 19/27 (70%) has a anti-HNA detected. The frequency of antibodies anti-HNA1a, anti-HNA1b, anti-HNA1c and anti-HNA2 at D0 were respectively 46,4%, 42,9%, 42,9% and 53,6%. The association between the HNA donor typing and anti-HNA antibodies of patients with day of engraftment, acute GVHD and TRM showed no statistically significant correlation. Conclusion: The HNA frequency found in donors is as described by the literature. However, the frequency of antiHNAs antibodies was quite high in the study population, even if the majority presented the disease for less than 12 months before the transplant. Although we don't find a correlation, further studies are needed to better assess the role of the HNA on the outcome of the HSCT. Disclosure of Interest: None declared. Introduction: Hematopoietic stem cell transplantation (HSCT) is the curative treatment option in most malign and nonmalign diseases. Chemotherapy and radiotherapy used in conditioning regimen can lead free radical increase and oxidative stress. In this study we investigated oxidative stress and anti-oxidant capacity in pediatric patients performed with HSCT. Material (or patients) and methods: We included 39 pediatric patients performed with HSCT in the study. 20 of patients were performed allogeneic HSCT from siblings and 19 of patients haploidentical HSCT. The blood samples were collected five times from both groups (MSD and Haplo) before and after conditioning regimen, and first, 30th and 100th days after HSCT. Total antioxidant status (TAS), total oxidative status (TOS) and oxidative stress index (OSI) were measured and calculated for each day in both groups by spectrophotometric methods. Results: TAS results of the patients with MSD and Haplo groups before and after conditioning regimen, and first, 30th and 100th days are shown in Figure 1 . In both groups, TAS decreased after conditioning regimen and then increased on 30th and 100th days after HSCT. But, TOS levels were not significantly different according to baseline, after conditioning regimen and HSCT. Moreover, while TAS levels did not differ between MSD and Haplo groups, TOS levels were lower in Haplo group. Conclusion: Drugs used in conditioning regimenlead to a decrease in anti-oxidant capacity and HSCT improves oxidative status. Disclosure of Interest: None declared. Introduction: Cardiac failure is a known complication after hematopoietic stem cell transplantation (HSCT), but predominantly occurs in predisposed patients with low output fractions or valvular heart disease. Hereby, we present a case of acute Takotsubo cardiomyopathy in a patient without preexisting cardiac comorbidities resulting in cardiogenic shock and ventilator therapy on day +1 after allogeneic HSCT. To our knowledge this is the first report of Takotsubo cardiomyopathy after HSCT. Material (or patients) and methods: The 62 year old female was diagnosed de novo AML M0. After induction therapy (cytarabine, mitoxantrone), 38% blasts persisted in bone marrow on day 15. Re-induction therapy with mitoxantrone, cytarabine and fludarabine lead to a clearance of blasts. Bridging therapy to HSCT with 5 cycles of decitabine was performed with no signs of AML recurrence. Apart from mild hypertension treated with beta blockers and AT1 antagonists, the patient had no history of cardiopulmonary disease. After reduced-toxicity conditioning therapy with treosulfan, fludarabine and ATG, the patient received 6,9 x 10e6 CD34 positive cells per kg bw from an HLA 10/10 matched unrelated male donor without any acute distress during re-transfusion of stem cells. However, eleven hours after transplant, she complained of acute chest pain, hypotension and dyspnea with decreased oxygen saturation that was refractory to non-invasive ventilation and was immediately transferred to the ICU in cardiogenic shock. Results: The ECG showed a heart rate of 136/min and an R-peak reduction from V1 to V3 without ST segment changes. High sensitive troponine, brain natriuretic peptide and creatinine kinase were elevated, but there were no signs of hemolysis. Coronary angiography was performed immediately after intubation. On examination there were no signs of coronary artery disease, but ventriculography and subsequent echocardiography revealed severe hypokinesia of the apical and medial walls (output fraction 30%) consistent with Takotsubo cardiomyopathy. The patient received intermittent vasopressor therapy and continuous dialysis with volume restriction. She was stabilized and extubated after 8 days. Echocardiographic follow up three weeks after transplant showed completely normalized ejection fraction. The patient was discharged with normal output fraction and is well and alive on day 135 after HSCT. Conclusion: Takotsubo cardiomyopathy is an infrequent cause of acute coronary syndrome and can be induced by physical and emotional triggers. In describing this case, we wish to remind physicans to take into account Takotsubo cardiomyopathy as a rare differential diagnosis in HSCT recipients with acute cardiac failure. Disclosure of Interest: None declared. Introduction: Patients frequently cite nausea and vomiting as one of the most distressing and debilitating side effects of chemotherapy. Chemotherapy-induced nausea and vomiting (CINV) can be divided into acute (24 or fewer hours after chemotherapy), delayed (more than 24 hours after chemotherapy). This distinction is made because acute CINV is believed to be mediated through serotonin receptor stimulation while delayed CINV is thought to involve multiple neurotransmitters, including opioid and neurokinin receptors. Chemotherapeutic agents have variable emetogenic potential that is affected by dose and method of administration. High-dose chemotherapy (HDC), often combined with TBI or total nodal irradiation of a varied amount, and stem cell rescue is a treatment modality applied to a wide variety of medical conditions. The delivery of high-dose therapy is almost always associated with a great degree of nausea and vomiting. Material (or patients) and methods: A clinical study of triple drugs combination (aprepitant+palonosetron+dexamethasone) was carried out to evaluate its efficacy in preventing both acute and delayed emesis after high-dose chemotherapy (HDC): 1) BEAM {carmustine+etoposide+cytarabine+melphalan} 2) Mel200 {Melphalan 200 mg/m 2 3) CarboPe {carboplatin+etoposide} 4) BuCTX {busulphan+cyclophosphamide} 140 patients suffered from various hematological malignancies were evaluated (70 in examinated group and 70 in control group), including BEAM -25 each, BuCTX -15 each, Mel200-20 each and CarboPe -10 each patients. The patients`groups were comparable for statistical analysis in terms of number of patients, their age, sex, weight and underlying diseases. Historical control groups of patients were treated with dexamethasone (dex) and palonosetron. The observation period started with the initiation of chemotherapy (0 h) and continued for 24 h after completion of the chemotherapy for acute phase, and during five days after finishing chemotherapy for delayed phase. The response rate of the study drugs was evaluated by the following 4-grade scale based on the condition of nausea and vomiting: highly, moderately or slightly effective and not effective. Results: The best results were observed (triple drugs combination) in the early phase after BEAM conditioning and in delayed phase after Mel200 high-dose chemotherapy. Conclusion: Triple drugs combination was more effective than palonosetron (+ dex) treatment in preventing CINV after high-dose chemotherapy before haematopoietic stem cell transplantation. References: Schmitt T, Goldschmidt H, Neben K, i wsp. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after highdose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol. 2014; 32: 3413-3420 Introduction: Graft failure is considered an important cause for morbidity and mortality following allogeneic HSCT. (Remberger M, et al. 2011) . Material (or patients) and methods: Twenty two fully HLAmatched, allogeneic bone marrow transplants for non malignant diseases have been performed from 2012 to 2015 at BMT Unit in Cairo University Children Hospital. One HLAmatched allogeneic BMT performed back in 2008. Thalassemia major (TM) forms 56.5% (n = 13) of total transplants so far, SAA contributes to 34.7% (n = 8) of total transplants while severe combined immunodeficiency (SCID) forms 8.69% (n = 2) of total transplants. Results: Seven patients suffered from graft failure (30.4%). Four patients were classified as primary graft failure (57.1%) while three cases (42.8%) were classified as secondary graft failure and they were secondary to acute graft versus host disease (aGVHD), CMV reactivation and non compliance to post transplant immunosuppressives respectively. Six patients (one male and five females) were cases of TM; received Busulfan (Bu)-cyclophosphamide (Cy)-antithymocyte globulin (ATG) as a conditioning regime and cyclosporin (CSA) as a prophylaxis for GVHD. While one patient was a case of SAA, male, received CY-Flu (fludarabine)-ATG as a conditioning regimen and CSA as prophylaxis for GVHD. Donors of stem cells in the seven cases were males. Four patients received peripheral stem cells (PSC) and three patients received bone marrow harvest in their 1 st transplant. Three patients were retransplanted using ATG (10 mg/kg/day) for 3 days and one patient received TBI (total body irradiation) -CY-FLU in retransplant. Outcome of graft failure was death in one (14.2%) S587 case, autologous recovery in three (42.8%) cases, engraftment post re-transplant in three (42.8%) cases. Two cases showed morbidity post engraftment; post retransplant. 
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years).
In the first 100 days post ASCT there were 22 hospital admissions corresponding to 18 patients (11,2%). Median hospital stay was 9 days (range 1-68 days). The majority of those were due to infectious complications (n = 10), renal insufficiency (n = 4), thrombotic events (n = 2), gastro-intestinal (GI) bleeding (n = 1) and other causes (n = 5). The main site of infection was GI tract (n = 5), followed by respiratory (n = 3) and urinary tract (n = 1) infections. Only in 1 case (GI infection) was an infectious agent identified -E. faecium. There was 1 death registered in this group of patients, attributed to disease progression. Patients with hospital admissions in the first 100 days post ASCT had shorter median survival (7,5 months) than those who were not admitted (P = 0,041). There was no statistical significant difference when comparing age (under or above 65 years), the number of previous lines of treatment, melphalan dosage (200 mg/m 2 vs 140 mg/m 2 or the number of mobilizations required. These factors were also not able to predict survival in our population. Conclusion: ASCT is widely used in MM patients, and is normally well tolerated, however a small proportion of patients require early hospital readmission within the first 100 days. In our group of patients this was the only factor associated with reduced survival. Disclosure of Interest: None declared. AB55 "A pilot study on the efficacy of Lactobacillus brevis CD2 lozenges in preventing oral mucositis by high-dose chemotherapy with autologous hematopoietic stem cell transplantation" S. Introduction: Treatment-induced oral mucositis is one of the most debilitating side effects from the patient's perspective and profoundly influencing QoL. OM is a pathological process characterized by mucosal damage, ranging from mild inflammation to deep ulcerations and affecting one or more parts of the alimentary tract, from the mouth to the anus, as a consequence of chemotherapy and/or radiation therapy.
(1) OM is associated with pain, bleeding, dysphagia, infections and food intake impairment, which can limit adequate nutritional intake. OM is strongly associated with bacteremia and sepsis due to E. Coli, P. Aeruginosa, and Candida. Two major events lead to OM; one direct injury caused by the ablative regimen, and local infections that develop on the damaged mucosal surface, which are exacerbated by neutropenia. Treatment and prevention of OM are palliative and the efficacy of most of the measures used have not been clearly established. Prophylactic measures employed are use of: chlorhexidine, soda bicarbonate rinses, acyclovir and ice. For treatment of OM and its associated pain local anesthetic, diphenhydramine, nystatin, or sucralfate are used alone or in combination as mouthwash. Several studies showed the successful treatment of OM with the strain of Lactobacillus brevis, due to the process of microflora manipulation. (2) The strain L. brevis produces high levels of the enzymes arginine deaminase and sphingomyelinase. Arginine deaminase converts arginine to ammonia and citrulline, reducing the amount of available arginine to be converted to nitric oxide, a major mediator of inflammation. Sphingomyelinase can hydrolyze platelet activating factor, a potent inflammatory cytokine, known to be associated with oral mucositis in radiation therapy. Material (or patients) and methods: The aim is to assess if the probiotic L. brevis CD2 lozenges can reduce the incidence and severity of OM in patients undergoing HSCT. We enrolled 16 patients (pts), affected by multiple myeloma and submitted to autologous HSCT at our division between March 2014 and February 2015. Eight pts received 6 L. brevis CD2 lozenges per day, from 14 days prior chemotherapy and till resolution of OM and reported all symptoms on a daily diary. The remaining 8 patients received standard OM prevention including chlorhexidine, saline rinses and nystatin. Results: Patients characteristics are summarized on TABLE 1. Fourteen out 16 pts developed diarrhea: stool cultures were positive for Candida in 2 pts and Clostridium difficile in 1 pt; 7/16 pts developed FUO and 2 sepsis. All pts developed OM with different grade: (grade I: 6; grade II:6; grade III:3; NA:1). One patient died during pancytopenia period for respiratory failure due to H1N1 influenza. Although there was a trend in a reduction of grade II and III OM, we found no statistical difference between the two arms. Conclusion: No differences were observed in terms of engraftment and complications post HSCT. In this preliminary experience the use of Lactobacillus brevis was safe and well tolerated. References: 1. Niscola P et al. Mucositis in patients with hematologic malignancies: an overview. Haematologica. 2007 Feb;92. Sharma A et al. Lactobacillus brevis CD2 lozenges reduce radiation-and chemotherapy-induced mucositis in patients with head and neck cancer: A randomized double-blind placebo-controlled study. Eur J Cancer. Disclosure of Interest: None declared.
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Evaluation of short term ruxolitinib tapering strategy prior to allogeneic stem cell transplantation for primary myelofibrosis through the transition of serum cytokines and growth factors; North Japan Hematology Study Group S. Shiratori 1,2,* , T. Introduction: Safety of the discontinuation of Ruxolitinib (Ruxo), a JAK1/2 inhibitor, prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelofibrosis (MF) is still controversial. "JAK ALLO Study" reported serious adverse events in early phase during allo-HSCT, indicating a rapid disease progression or withdrawal symptom by the discontinuation of Ruxo, 1 while such events were not described in several retrospective studies. Furthermore no previous study evaluated the safety of the discontinuation of Ruxo prior to allo-HSCT in association with changes in serum levels of cytokines or growth factors. Material (or patients) and methods: We conducted a pilot study in two patients with primary MF treated with Ruxo prior to allo-HSCT. Ruxo was tapered off 6 days before the initiation of reduced intensity conditioning regimen using fludarabine (180 mg/m 2 ), intravenous busulfan (9.6 mg/kg) and 4 Gy total body irradiation. Primary endpoints were the following: 1) Engraftment and survival at 4 weeks after allo-HSCT, 2) Analysis of serum cytokines and growth factors before and after Ruxo and during allo-HSCT. This study was approved by the Ethics Board in our hospital and the study protocol is registered in University Hospital Medical Information Network Clinical Trials Registry (UMIN000019421). Results: Both patients improved splenomegaly after the administration of Ruxo and no disease progression or withdrawal symptom was developed after the discontinuation of Ruxo (Figure) , and achieved engraftment with complete donor chimerism by day 28 after allo-HSCT. Serum levels of VEGF, IL-6 and sIL-2 R were decreased after the administration of Ruxo. However, those of IL-6, sIL-2 R and MCP-1 were significantly increased after the discontinuation of Ruxo. IL-6 and sIL-2 R persisted higher serum levels until day 28 after allo-HSCT, while those of MCP-1 was decreased to baseline on day 28. Serum level of VEGF was also slightly increased after the discontinuation of Ruxo; however, the elevation was temporary and showed a stable transition during allo-HSCT ( Figure) . Conclusion: Our preliminary study suggests that Ruxo tapering strategy 6 days prior to initiation of conditioning regimen is safe without causing withdrawal symptom of Ruxo. Serum level of VEGF might reflect disease status of MF possibly unaffected by engraftment or GVHD during allo-HSCT, although these results need to be validated in a larger study. Introduction: Idiopathic pneumonia syndrome (IPS) post haematopoietic stem cell transplantation (HSCT) is a rare complication, difficult to treat, with a poor prognosis and often fatal.
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1,2 The aetiology remains disputed, but conditioning, graft versus host disease (GvHD) and occult infection have been implicated. Recent murine studies implicate endothelial cell (EC) activation and injury.
2 as demonstrated by endothelial leak of fibrin, endothelial apoptosis, veno-occlusive disease (VOD), venous embolization and fibrin deposition, pulmonary hypertension (PH), and pulmonary vascular intimal hyperproliferation on histopathological specimens. 2, 3 Historically, few lung biopsies were performed on our patients with IPS. Results have been variable, with no underlying disease process described. We retrospectively examined lung biopsies in a primary immunodeficiency (PID) paediatric HSCT cohort, specifically looking for EC activation/injury. Material (or patients) and methods: PID patients who underwent HSCT between 01/2000-07/2015 and had a post-HSCT lung biopsy were identified from the pathology database. Patient records were reviewed and lung biopsies re-examined for signs of EC activation/injury. Results: 313 PID patients underwent HSCT, 9 were identified as IPS with 8 having biopsy material available. All presented with respiratory distress. 6 received pre-HSCT conditioning. Median time of symptom onset D+11 post-HSCT (range D 1 of conditioning -D+36 post-HSCT), 2 had symptoms from birth. 8 required mechanical ventilation. 2 received Defibrotide (DF) for VOD. Mortality was 88%. Histology: None had signs of viral, bacterial or fungal infection. 5 had widespread capillary leak of fibrin in alveolar spaces, no patients showed evidence of active VOD, 4 had arterial myointimal thickening, and therefore PH, 2 of which had no alveolar capillary fibrin leak. 2 had Bronchiolitis Obliterans (BO). 1 had fibrin deposition, intraepithelial T cells and atypical mildly reactive pneumocytes. At post mortem, 1 patient had intra-alveolar fibrin, VOD, PH, intraepithelial T cells and BO. 1 patient had rhinovirus identified from bronchoalveolar lavage but had no reactive inflammatory cells. No micro-organisms were identified from other patients. 4 had ground glass appearances on Chest X-Ray/CT, 3 had non-specific consolidation, 1 demonstrated bilateral upper zone collapse, 1 had no radiological abnormalities. Conclusion: Our patients with clinically and radiologically unexplained respiratory symptoms, designated IPS, all show underlying disease processes associated with EC damage, the cause of which remains unclear. Possible factors include previous infection, conditioning agents or the underlying PID with inflammation. Further work, using cellular markers for EC activation and damage, is needed to confirm EC damage in these biopsies. DF is an agent that modulates EC damage 2 and may be useful in the treatment of these patients, although stratifying which patients will benefit from DF requires further study. Introduction: Chylothorax is lymphatic fluid leakage into pleural space with high triglyceride content and milky appearance. Etiology could be congenital, trauma, malignancy or granulomatous infections. This report describes multifactorial etiology of bilateral chylothorax in a child after stem cell transplantation (SCT). Material (or patients) and methods: A 16 years old male with monosomy 7 positive refractory AML had undergone SCT from a matched related donor with total body irradiation based conditioning and secondary prophylaxis with voriconazole. Results: At 3 months posttransplant with 100% donor chimerism and monosomy negativity he had dysphagia, vomiting, anal pain and fever which prompted ampirical antibiotics. On the second day facial angioedemateous like swelling, resistant to steroids and antihistaminics was noticed with no sign of extramedullary relapse in paranasal and neck CT. On the 7th day he developed diarrhea. Although rectal biopsy proved severe intestinal GVHD no therapy was given as diarrhea resolved. Fifteen days later liver function tests increased and biopsy verified GVHD that lead to tacrolimus and steroid treatment. While performing liver biopsy milky appearing fluid was noticed. Abdominal US showed perihepatic fluid (6 mm). Invasive aspergillosis history and newly developed cough directed a thorax CT which displayed bilateral pleural (20mm in left, 24 mm in right) effusion and 5mm cavitary lesion in the left lung. Thoracocentesis drained chylohemorrhagic fluid with a triglyceride content of 1150 mg/dl and galactomannan and aspergillus PCR positivity. Central venous line was removed for leakage suspicion. As new lesions under voriconazole have emerged, liposomal amphotericin B (L-AMB) and fatrestricted oral diet and ocreotide were started. In the meantime although morphologically in remission monosomy 7 positivity was detected that encouraged tacrolimus withdrawal. At 1st month of ocreotide and L-AMB treatment he developed fever with increased coughing. Thorax CT showed ground glass appearance and enlarged effusion (52 mm left, 13mm right). Inflammatory fluid was drained and caspofungin was added to L-AMB along with wide spectrum antibiotics. No microorganism was detected in further tests. Besides ocreotide he had TPN nil by mouth for 10 days which caused decrease in pleural effusions (12 mm left, 7mm right). He received combined antifungal therapy for 8 weeks with resolution of the lesions. Repeated bone marrow examinations showed remission and monosomy negativity. He is now well at 16th months posttransplant with minimal pleural effusion receiving ocreotide and cyclosporine for upper GI GVHD. Conclusion: Chylothorax is an uncommon cause of pleural effusion in children. As treatment should be based on determining the underlying cause, it is of paramount importance to define the etiology. In the absence of apparent risk factors such as trauma this could be difficult. That is particularly challenging in the transplant setting since the etiology could be multifactorial as in our patient. Although the beginning was chylous ascites the bilateral nature of chylothorax precluded us from considering it being the origin. We assume that the reason of bilateral chylothorax in our patient is iatrogenic trauma by TBI as well as noniatrogenic trauma by forceful emesis and coughing associated with GVHD and aspergillus infection where all could be common in the posttransplant setting. Disclosure of Interest: None declared.
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Total body irradiation (TBI)-based versus chemotherapybased myeloablative conditioning regimen before allogeneic stem cell transplantation (allo-sct) for acute myeloid leukemia (AML Introduction: Cyclophosphamide combined with TBI or busulfan are the most widely used myeloablative conditioning regimens in patients with AML. Recent data regarding their comparative effectiveness are lacking. Material (or patients) and methods: In this study we retrospectively assessed the outcome of 103 patients with AML in first or second complete remission (n = 70) and refractory disease (n = 33) who received myeloablative conditioning either with a TBI-based (n = 47) or chemotherapybased (n = 56) regimen for SCT from an HLA-matched sibling (n = 56) or an unrelated donor (n = 28) or a haploidentical donor (n = 19). The conditioning regimen sequence was compared according to overall survival (OS), leukemia-free survival (LFS), TRM, leukemia relapse and GvHD. Results: Overall survival of all patients was 50% at 3 years. According to disease status, 3 years probabilities of OS were 64% in CR and 22% in refractory disease at time of transplant (Po 0.0001). Three-year probabilities of survival were 59% and 43% for TBI and chemotherapy (P = 0.1). Three-years probabilities of DFS were 39.5% and 20.5% for TBI and chemotherapy (P = 0.3). In multivariate analysis for OS, the indipendent factors statistically significant were disease status at transplant and GvHD grade III-IV. The cumulative incidence of acute GvHD were 38% in TBI arm and 61% in chemotherapy arm (P = 0.02). Corresponding incidences of transplant-related mortality (TRM) were 10% and 16% respectively in patients receiving TBI compared chemotherapy. Conclusion: In conclusion in our experience TBI is associated with superior outcomes compared with chemotherapy in patients with AML, an important result with the use of TBIbased conditioning regimen is the less development of acute GVHD (38%) respect to chemotherapy-based (61%). . This is equivalent to replace Bicnu by the Busilvex and increases the dose of 46.67% Aracytine. Material (or patients) and methods: From January 2014 to June 2015, we retrospectively analyzed toxicities of these two regimens: BEAM versus BAM in a paired study, including 29 patients treated with BEAM and 21 with BAM. The average patients' age at D0 was 50 years (in BEAM group) and 51 years (in BAM one). There were no significant differences between the two groups regarding the stage of the disease. Most of the patients were followed for NHL (16 NHL and 5 MDH in the BAM group, 20 NHL and 9 MDH in the BEAM one).
Results: Study of the short-term toxicities reveals that conditioning BAM is more toxic considering platelets reconstitution with a median of 14 days for the BAM versus 4.5 days for BEAM (P = 0.013) for platelets above 50 G/ l, a median number of transfusion 8.48 versus 6.33 MCP (P = 0.08), and a higher number of patients with severe mucositis (P = 0.0001). Nevertheless, there is no significant difference in hospitalization duration, aplasia length, and short-term infectious complications. Long-term toxicities will be developed, available in March 2016 with a follow-up of 1 year. Conclusion: In conclusion, BAM conditioning regimen induces longer thrombocytopenia, higher transfusion needs and increasing risk of bleeding and transfusion complications. The gastrointestinal toxicity is increased with more frequent and more severe mucositis, promoting undernutrition. A complement of this study will be presented regarding the long-term effectiveness of this type of procedure and its delayed toxicity. Disclosure of Interest: None declared. The lymphocytes count was41500 on day +150 posttransplant. The last IVIG transfusion was on D+38 and her IgG is4600 mg/dl with normal IgM levels. She is now D +335 post-transplant doing fine without any complications or infections apart from self-clearing low viremia of CMV virus on D+243 (CMV PCR was o1000). Patient 2: T -B -NK -male SCID patient diagnosed on 1.5 months old as he was the 2 nd affected and 1 st diagnosed member in a consanguineous family. He received BCG vaccine; therefore, he received anti-tuberculous drugs. He was transplanted at 3.5 months old from his fully matched brother. Pre-transplant his WBC was ranging from 1000 to 2500cells per milliliter and the ALC was 150 cells per milliliter. He was transplanted while he had severe Klebsiella pneumonia and Klebsiella bacteremia, all these infections were cleared post-transplant. He developed acute moderate skin GVHD which was treated by steroid. T and B cell engraftment were on D+75 post-transplant. The lymphocytes count was41500 on day +75 post-transplant. D 75+: TLC: 11,000 ALC: 16% (1760). Introduction: Allogeneic transplantation (Allo-SCT) in multiple myeloma is controversial mainly due to the relatively high non-relapse mortality (NRM). Treosulfan is a prodrug of a bifunctional alkylating agent which has both myelotoxic and immunosuppressive properties (1) . Recently a regimen of moderate dose treosulfan has been used in combination with fludarabine and ATG for treatment of malignant lymphoma and a small number of patients with multiple myeloma with low transplant related mortality (2, 3) . The aim with this retrospective single-center study was to evaluate recent transplants particularly after conditioning with treosulfan plus fludarabine (TreoFlu). Material (or patients) and methods: The study comprised 39 patients (median age: 46 years) that underwent Allo-SCT between 2000 and 2015. Twenty-five patients were in very good partial response or better (≥ VGPR) and 14 in less than VGPR. Results: The 3 years overall survival (OS) for the patients allografted after and before year 2008 was 89% vs 41% respectively (HR = 0.14 (95% CI 0.03-0.65, P = 0.01) and for patients transplanted in ≥ VGPR and P = 0.18). Eleven of the 22 patients transplanted after 2008 received TreoFlu. Only one of these patients died of NRM. Introduction: Prognosis of relapse of hematologic malignancy after allogeneic stem cell transplantation remains dismal. Second allogeneic transplantation represents a valid clinical option in such patients. Toxicity of the preparative regimen for second transplanation may sometimes limit a decision making process in offering the patients a second graft. Goal was to evaluate the toxicity and tolerability of treosulfan, fludarabine and rabbit ATG (Thymoglobuline, r-TG) preparative regimen in the setting of the second allogeneic stem cell transplantation for disease relapse. Material (or patients) and methods: We evaluated all patients who underwent second allogeneic transplantation for the relapse of their malignant disorder after the first allograft during years 2012-2015 at our department. Preparative regimen in all patients consisted of treosulfan 12 g/m2 for 3 days, fludarabine 30 mg/m2 for 5 days and r-TG 6 mg/kg. All patients received calcineurin inhibitor and mycophenolate mofetil as GVHD prophylaxis. Day +28 and +100 mortality, platelet and neutrophil engraftment as well as infectious and acute non-infectious complications were recorded. Results: We identified 9 patients (8 males and 1 female), median age 47 years (33-65 years) who underwent second allogeneic graft for relapsed disease after the 1st transplantation. 5 patients had acute myeloid leukemia or myelodysplastic syndrome, 2 patients had acute lymphoblastic leukemia, 1 had chronic lymphocytic leukemia and 1 primary myelofibrosis. 3 patient were in subsequent CR of the disease and 6 in relapse. 7 patients received 10/10 matched unrelated peripheral blood stem cell graft and 2 patients received 9/10 mismatched unrelated peripheral blood stem cell graft. All patients engrafted in platelets at median D+13 (9-26) and in neutrophils at median D+14 (11-20) . Median D+28 donor chimerism was 100% (5-100%), one patient experienced graft failure at D+28 due to HHV-6 and subsequently died of HHV-6 encephalitis (confirmed). No other early deaths until D+100 were observed. Only 2 patients had mucositis, only one being grade 4. All 9 patients experienced episode of fever, 5 of them diagnosed with G-bloodstream infection and 2 of them with G + blodstream infection. 2 patients had pneumonia. All patients recovered from their respective complications. Overall D+100 non-relapse mortality was 11.1% (1/9 patients Introduction: Allogeneic hematopoietic stem cell transplantation (HSCT) in advanced phase myelofibrosis (MF) is a valid curative approach, but it is charged of an high risk of graft failure or rejection. This complications is though to be related to the particular condition of marrow micro-environment, but also spleen enlargement can play a role either in sequestering donor stem cells or in preserving autologous foci of stem cells. A proportion of MF patients (pts) can benefit from splenectomy before HSCT but such procedures have been associated with substantial surgical morbility. Considering these, we have tried an alternative approach with splenic irradiation immediately before HSCT in a limited number of MF pts, and we evaluated the post transplant outcome. Material (or patients) and methods: We selected 5 pts with advanced chronic phase MF (according to Cervantes scoring system 2 pts intermediate-2 and 3 pts high risk IPSS) and one patient with acute evolution of MF; only one have been treated before with Ruxolitinib, all of them have a great spleen enlargement ranging from 18 to 25 cm (ultrasonography measured). All pts received a schedule of fractioned splenic irradiation as a component of conditioning regimen (4 Gy divided in 4 daily doses each of 1 Gy, between -15 to -5 days to transplant). Conditioning regimen was Busulfan-Fludarabine for 4 pts, reduced dose Busulfan-Fludarabine for 1 patient and ThiotepaBusulfan-Fludarabine for 1 patient. Results: after fractioned splenic irradiation and fludarabinebased conditioning regimen, all pts showed remarcable spleen volume reduction within two months after HSCT; 5/6 pts obtained successful donor cells engraftment, without severe complication related to splenic irradiation. Median neuthrophil and platelet recovery (4500/mm 3 and 420.000/mm 3 ) was 27 and 36 days respectively. After 2 months, chimerism status was 100% donor for 4 pts and 80% donor for 1 patient. Three pts had a good outcome and are actually disease free with a complete chimeric status after 39, 27 and 12 months from HSCT. One patient relapsed and rapidly presented a fatal leukaemic evolution two months after HSCT, one patient relapsed with autologous haemopoiesis 6 months after HSCT. The only patient who did not engraft remained cytopenic surviving 12 months. Conclusion: Splenic irradiation immediately before HSCT could be considered a safe and alternative option to splenectomy for MF pts with massive splenomegaly, in order to obtain the improvement of donor engraftment. Our limited experience shows that also these pts can have a favourable outcome. A largest number of cases would be required to discriminated the real advantage of this strategy. Disclosure of Interest: None declared.
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Results of observational study on treatment patterns in adult patients with hematological malignancy (HM) undergoing hematopoietic stem cell transplantation (HSCT) Introduction: Available information on HSCT comes mainly from US and European countries. The purpose of this multinational prospective observational study was to collect data on treatment patterns of HSCT in HM in some non-US and non-EU countries. Material (or patients) and methods: 500 patients (pts) were planned. Main eligibility criteria: adult pts with HM starting conditioning treatment in purpose of allogenic (allo) or autologous (auto) HSCT, written informed consent. Primary endpoint: to describe type of conditioning used in HSCT. Visit at 3 and 6 months after HSCT were planned. Results: 500 eligible pts were recruited over 13 months in 9 countries, median age was 44 years old (min-max: 18-72), PS was 0 in 53.0% pts and 1 in 40.4% pts. HM were multiple myeloma (MM) (37.2%), acute myeloid leukemia (19.8%), nonHodgkin lymphoma (14.4%), Hodgkin lymphoma (HD) (13.6%), and acute lymphoblastic leukemia (9.2%). Myeloablative (MA) conditioning regimen was most frequently used in all tumor types (overall 78.6% pts) and in allo and auto HSCT (80.3% and 76.5%, respectively). Source of HSC was peripheral blood in 91.4% HSCT. Median day of engraftment was 13. Graft failure was reported in 18 pts (10.1%) with allo HSCT and 2 pts (0.6%) with auto HSCT. In 309 pts auto HSCT from peripheral blood only, mobilization was chemotherapy (CT)+G-CSF in 40.5% pts, CT alone in 32.0% pts and G/GMCSF alone in 25.2% pts. CXCR4 antagonist was used in 2.3% pts. Median number of CD34+ cells prior first apharesis was 47 /μL (min-max: 0.7-11748) and median number of apharesis was 2 (min-max: 1-8).
In 179 pts allo HSCT, 43.6% had ABO mismatch. GvHD prophylaxis was part of conditioning regimen in 26.8% pts and was mainly rabbit ATG (93.0%). Acute GvHD any grade was reported in 38.0% pts and grade 3-4 in 12.3% pts, and chronic GvHD any grade in 16.8% pts and grade 3-4 in 1.7% pts. Majority of HSCT were CMV D+/R+ (73.2%). CMV prophylaxis at 3 months was given in 29.1% pts and median duration was 90 days (min-max: 9-180). CMV reactivation was reported in 31 pts and CMV infection in 19 pts. Febrile neutropenia, diarrhea and neutropenic bacterial infection were the most frequent events (47.6%, 24.6%, and 14.8%, respectively). Conclusion: MA was the most frequent conditioning regimen used in both allo and auto HSCT with similar complications to western countries, and majority had auto HSCT. Introduction: In Europe rabbit Anti-Thimocyte-Globuline (ATG) is widely employed in patients submitted to Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT) in order to reduce acute and chronic Graft versus Host Disease (GvHD). ATG seems to be very effective in reducing GvHD, but a significant increase of infective complications is often observed in these patients (pts). This fact and the reduction of "Graft versus Leukemia" effect make the use of ATG in MUD-HSCT a matter of debate nowadays. We evaluated the immunologic recovery in pts treated with ATG during the first year after MUD-HSCT and its correlation with the insurgence of opportunistic infection in the same period, excluding infection appeared before hematological uptake. Material (or patients) and methods: We considered 32 pts, affected by hematological malignancies, submitted to MUD-HSCT who received ATG 7.5 mg/Kg during the conditioning regimen. We discriminated two categories: pts who developed opportunistic infection (12 pts) and pts without infection (20 pts) in the first year after HSCT. We analysed immunological recovery (lymphocyte sub population count) in these two series at two, four, six eight and twelve months after HSCT. According to the type of transplant: 47 (25%) were autologous and 138 (75%) allogeneic, of which 48 from MSD (34,8%); 78 from MUD (56,5%) and 12 from MMFD (8,7%). Stem cell sources included bone marrow (n = 97), peripheral blood (n = 87) and cord blood (n = 1). PBSC were the source of transplant in 45/47 autologous recipients, 2/47 received BM. The majority of allo transplant recipients (95/138) received BM, 42/138 PBSC and 1/138 CB. GvHD grade = 42 was diagnosed in 40/138 allotransplant recipients (29%). Statistical analysis of OS was performed using Kaplan-Mayer method and long rank and chi square tests. Statistical significance was considered o0,05. Results: With a median follow-up of 3-years overall survival (OS) was 0,71 in the whole group of 185 patients. According to the type of transplant OS in MSD recipients was 0,82; in MUD and auto 0,65; haplo 0,47 (P = 0,01). In allo transplants OS was significantly higher in BM recipients comparing to PBSC recipients (0,76 versus 0,5 P = 0,002 Introduction: As the survival of allo-HSCTs is constantly improving, more and more patients, especially the youngest, are susceptible to late complications. Here, we present our institutional experience of late effects in the first 6 years (y) following pediatric allo-HSCT, comparing malignant versus non-malignant indications for HSCT. Material (or patients) and methods: All children allotransplanted between 2009 and 2015 were included in this single-center retrospective cohort. Screening was carried out in accordance with international published guidelines. 1 Of 76 transplanted patients, 58 were included in the analysis; 18 excluded due to short (o6 months) follow-up. Results: Median age at HSCT was 9.8y; the non-malignant group was younger. HSCT indications were evenly divided between non-malignant (NMD) and malignant diseases (MD) (82% of which were ALL). Ten patients (17%) required a 2 nd HSCT. Pre-transplant characteristics are listed in table 1. Median follow-up was 3.3y. Twenty one patients (36%) had cGVHD; the rate of cGVHD was double in patients with MD, and all 5 severe cGVHD cases occurred in this group. The common affected organs were skin & joints, GI tract, lungs, Table 1 : Transplant related deaths in alloHSCT recipients. Conclusion: These data confirm that even in the first years following allo-HSCTs, pediatric patients are prone to a diverse array of complications, mainly endocrine. The underlying disease appears to affect morbidity: children with MD have a two-fold risk of developing cGVHD and late effects (other than vitamin D deficiency), versus NMD. These differences could be attributed to higher cumulative induction/conditioning radio-chemotherapy dose in the MD group. Although the vast majority of deaths were in patients with MD, most deaths were attributed to disease relapse; therefore no conclusion can be drawn regarding late transplant related mortality in MD versus NMD. Study limitations include the relatively small cohort, loss to follow-up and uncertainty regarding patient adherence to screening guidelines. As long-life follow-up is needed for this unique population, a continuing surveillance of the cohort study is planned. Introduction: Donor lymphocytes infusion (DLI) is a recognised practice for the treatment of positive minimal residual disease (MRD) after stem cell transplant. Its use is not indicated in the presence of GVHD. In the cases of GVHD post DLI, the beneficial effect could be impaired by the use of steroids. Material (or patients) and methods: We report our experience in the management of a child with acute skin GVHD and positive MRD detected after haploidentical stem cell transplant (haplo SCT) for ALL. Results: Two years old female, diagnosed of precursor B acute lymphoblastic leukemia. Treated as per the national protocol. Indication for allogenic stem cell transplant for positive MRD after consolidation chemotherapy. Because of the absense of matched related or unrelated donor, father was selected as haploidentical donor (for NK alloreactivity). Prior to transplant she was in complete remission (CR) with negative MRD. Conditioning regime: thiotepa, busulfan and fludarabine. GVHD prophylaxis: Post-infusion ciclophosphamide on days +3, +4 and tacrolimus+MMF from day +5. Unmanipulated peripheral blood was infused (CD34+ 6x10 6 /kg). Neutrophil engraftment on day +16. On day +23 she was diagnosed of acute gut and skin GVHD (grade II). She was started on systemic steroids (methylprednisolone 2 mg/kg/day) and presented very good response by day 7, so steroids were tapered. Bone marrow aspirate (BMA) on day +30: full donor chimerism, negative MRD. MMF discontinued on day +30 as per protocol. BMA on day +60 showed morphological CR, positive MRD (0.11%) and 96% donor chimerism. Tacrolimus and prednisone were suspended. She received a DLI on day +70 (CD3+ 1x 10 5 /kg). Prior to DLI she presented malar exanthema with no other signs of GVHD. One week after the DLI she presented with generalised macular exanthema including palms and plants compatible with skin GVHD. No other organs affected. She was started on topical steroids and extracorporeal photopheresis (ECP, 2 sessions per week) to avoid the use of systemic steroids. BMA on day+80: MRD 0.02%. In the context of GVHD no more DLI were administered. MRD on day +90: 0.007%. GVHD progressively improved with ECP treatment. She is now a year post-transplant. MRD remains negative and skin GVHD is resolved. ECP has now been stopped after 23 sessions. Conclusion: DLI is a useful tool in the management of positive MRD early after transplant in paediatric ALL. ECP permitted the avoidance of steroids in GVHD recurrence after DLI. [AB68]
Material (or patients) and methods: We aim to present the outcome of six pediatric patients with PID transplanted at the Bone Marrow Transplant Center in Timisoara/ Romania. Three children with x-linked chronic granulomatous disease (CGD), one patient with Griscelli syndrome type 2 and hemophagocytic lymphohistiocytosis (HLH) and two other twins with IL-7 receptor deficient T -B + NK + severe combined immunodeficiency (SCID) were transplanted from matched related or unrelated donors at our Center between 2008-2014. All three patients with CGD received myeloablative regimens and the grafts were bone marrow in two and peripheral blood stem cells (PBSC) in one of the patients. The patient with Griscelli received also a myeloablative regimen and PBSC.The two SCID's had a non-myeloablative conditioning and were transplanted with bone marrow simultaneously. Results: All of the patients engrafted, presenting complete donor chimerism early after the transplant. Regarding transplant specific complications, two patients presented acute graft versus host disease and the child with HLH developed severe veno-occlusive disease early after the transplant. Two out of the three patients with CGD are cured, the third died following severe pneumonia at 3 months posttransplant with 100% donor chimerism and normal function of granulocytes and monocytes. One of the twins with SCID is well with 100% donor chimerism and good immune reconstitution, the other one died of pulmonary complications, whereas the patient with HLH is also in remission, with a mixed chimerism. Overall, four of six patients are alive and well with complete recovery of their severe immune deficiency. Conclusion: HSCT provided cure for two thirds of the patients with PID. Although HLA-matched sibling donors are the best option for these patients, the advances in HLA typing and unrelated donor search have made HLA-matched unrelated donor transplants a very good alternative. Disclosure of Interest: None declared. Pediatrics, Khoo Teck Puat-National University Children's Medical Institute, National University Hospital, Singapore, Singapore, Singapore Introduction: We retrospectively reviewed the outcome of 33 hematopoietic stem cell transplantation in 25 patients with non-malignant diseases treated at National University Hospital, Singapore, over the period of 10 years, from June 2005 to August 2015. Material (or patients) and methods: The age of the patients ranged from 7 months to 17.5 years with a median of 4.76 years. There were 16 male and 9 female patients. The conditions managed were namely that of Thalassaemia (n = 8), Aplastic Anaemia (n = 4), Haemophagocytic lymphohistiocytosis/ Lymphoproliferative Disorder (n = 6), Immunodeficiencies (Chronic Granulomatous Disease (CGD), Severe Combined Immunodeficiencies (SCID), CD40 Ligand deficiency) (n = 4) and others (Congenital Haemolytic Anaemia, Diamond Blackfan Anaemia, Dyskeratosis Congenita) (n = 3). Results: There were 6 matched sibling donor (MSD) transplants, 2 matched related donor (MRD) transplants, 17 matched unrelated donor (MUD) transplants and 8 haploidentical transplants. Stem cell sources were bone marrow (n = 15), peripheral blood stem cell (n = 15) and dual umbilical cord blood (n = 2). TNC count ranged from 1.74 x 10
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Results: Cumulative incidences of neutrophil and platelet engraftment by day 28 were 100%. After median follow-up of 6.2 years (range, 0.8-17.4), 8 of 12 patients survived. Cumulative incidence of treatment-related mortality (TRM) and relapse were 9% and 35.8%. Event-free survival (EFS) and overall survival (OS) after HCT were 58.3% (95% CI, 44%-73%) and 66.7% (95% CI, 53%-80%), respectively. WHO classification did not significantly affected EFS after HCT for pediatric MPAL patients (P = 0.371). Also, time to remission (less than 45 days or not) and stem cell donors were not significantly associated with EFS after HCT. Conclusion: Many studies have reported that patients with MPAL had poor prognosis, and patients with T/myeloid phenotype had a worse outcome than patients with B/ myeloid phenotype. We found that WHO classification 2008 for MPAL was not significantly associated with patients' outcome after HCT and that patients with MPAL, T/myeloid, NOS had more favorable outcome compared to historical data. Our data suggested that HCT after complete remission may improve the outcome of pediatric patients with MPAL, particularly T/myeloid phenotype. This study needs to be confirmed in larger, prospective studies including more pediatric MPAL patients. Disclosure of Interest: None declared. Introduction: Non-relapse mortality following allogeneic hematopoietic stem cell transplantation has rapidly decreased during the past 15 years among pediatric cancer patients in developed countries, but little information about non-relapse or relapse-related mortality is available for pediatric cancer patients in developing countries. We aimed to estimate the cumulative incidence of non-relapse and relapse-related mortality following allogeneic hematopoietic stem cell transplantation among pediatric cancer patients in Argentina. Material (or patients) and methods: Individuals eligible for our study were aged o20 years when diagnosed with cancer and underwent allogeneic hematopoietic stem cell transplantation between September 1, 1998 and May 31, 2015 at Hospital de Ninos Sor Marlia Ludovica in La Plata, Argentina, which is a regional referral center for pediatric transplantation. Our outcomes of interest were non-relapse and relapse-related mortality, where non-relapse mortality was defined as mortality from any cause other than cancer progression. These outcomes were prospectively documented following transplantation until July 31, 2015. We used a competing-risks framework to estimate cumulative incidence and 95% confidence limits (CL) of nonrelapse mortality and relapse-related mortality. Results: Our study population comprised 89 pediatric cancer patients, of whom 44% were aged o10 years at transplantation, 63% were male, 90% were diagnosed with leukemia, and 92% were transplanted with stem cells from related donors. We observed 39 deaths (24 relapse-related and 15 nonrelapse) during 280 person-years of follow-up (median = 3.6 years, interquartile range = 1.2-8.4). Infections or infectionrelated consequences were the most common causes of nonrelapse mortality (40% of non-relapse deaths). The 5-year cumulative incidence of non-relapse mortality was 18% (95% CL: 10%, 26%) and the 5-year cumulative incidence of relapserelated mortality was 31% (95% CL: 21%, 42%). All non-relapse mortality in our population occurred within 14 months of transplantation, whereas the latest relapse-related mortality occurred nearly 10 years after transplantation. Conclusion: Our results suggest that relapse-related mortality is the predominant reason for mortality 5 years post-allogeneic hematopoietic stem cell transplantation among pediatric cancer patients in Argentina. Nevertheless, non-relapse mortality is substantially higher in our population than posttransplant pediatric cancer patients in Europe (cumulative incidence = 9.0% Introduction: The number of registered donors worldwide is increasing and frequently there is a choice between several HLA identical stem cell sources. To find the best donor, currently only limited information like gender, CMV etc. are available. The case of a successful stem cell transplantation (SCT) of an HIV infected patient ("Berlin Patient") with leukemia in 2007, where a donor with HIV resistance (homozygosity for CCR5-d32) was identified, emphasized the potential of individualized stem cell therapy. Material (or patients) and methods: EpiStem (www.epistemproject.org) is a collaborative consortium to guide and investigate the potential for HIV cure in infected patients requiring allogeneic SCT for hematological disorders. Donor requests for 15 patients were collected between 2012 and today. Potential donors and cord blood sources were tested for the CCR5-d32 mutation. The DKMS Donor Navigator was used to pre-screen donors in the DKMS registry. Results: The EpiStem Project has generated a prospective observational cohort of 15 cases of allogeneic SCT in HIV-1-infected individuals with life-threatening hematological malignancies. Five cases had a CCR5-d32 donor and 10 had a CCR5 wild type donor. In 3 cases the donor cells came from a cord blood unit and in 12 cases from an adult donor. So far 3 patients have successfully passed the 6 months follow-up after transplantation, and 6 patients have died after transplantation, despite achieving full donor cell chimerism in some cases. Preliminary analysis of virological and immunological data from blood and tissue samples reveal a systematic reduction of HIV-1 reservoirs to very low levels. The DKMS Donor Navigator was successful in 5 of 11 requests even though not all patients entered into the EpiStem project (Table 1) . Conclusion: In the past additional genetically information from donors was not available or very hard to access. Requests for blood samples during CT/workup are possible but commonly limited to a few selected donors. In case of the "Berlin patient" the screening of 62 donor samples took several months of time which is generally too long for most of the patients. Prescreening of cord blood units was the first step in generating a preemptive data base of additional stem cell source information. The most recent development of the DKMS Donor Navigator allows transplant centers to prescreen a large number of donors already typed for additional and beneficial information (currently CCR5 and KIR1). In case of searches of CCR5-d32 homozygous donors for HIV infected patients the DKMS Donor Navigator was successful in 45% of the cases. Identifying genetic determinants in transplantation, prescreening the donors, and sharing this information with the clinicians may deeply improve the quality of donor selection in the future. Disclosure of Interest: None declared.
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Infusion rates of the graft do not influence early engraftment following intra bone marrow transplantation in a DLA-identical canine transplantation model S. Introduction: Intra bone marrow transplantation (IBMT) of hematopoietic stem cells (HSC) might be a promising alternative to conventional intravenous application of HSC in order to improve the homing efficiency and to accelerate the early engraftment after transplantation. Especially for transplantation of limited cell numbers the IBMT might prevent a delayed engraftment. Here we investigated the impact of the graft infusion rate on the hematopoietic recovery as well as on the engraftment kinetics after allogeneic IBMT in a canine DLA-identical littermate model following reduced intensity conditioning. Material (or patients) and methods: Dogs were conditioned with 4.5 Gy total body irradiation. The graft volume was reduced by buffy coat centrifugation and dogs obtained 2x25ml into the femur and humerus simultaneously. The infusion period of the graft was 10 min in group 1 (IBM10, n = 8) and 60 min in group 2 (IBM60, n = 7). Cyclosporin A (15 mg/kg, BID) was administered as immunosuppression from d-1 until d+35 post transplantation. The hematopoietic recovery was monitored daily by blood counts and the development of the chimerism for the peripheral blood mononuclear cells (PBMC) and granulocytes was determined weekly. Results: All animals of both groups engrafted. One dog died at d+15 (infection) of the IBM10 group and was therefore not included. The median number of infused total nucleated cells was 4.1*10 8 /kg in both groups (IBM10: range 2.3-6.0*10 8 /kg, IBM60: range 1.8-4.4*10 8 /kg; P = n.s.). The infused CD34 + cell numbers were median 3.2*10 6 /kg (range: 1.2-10.0*10 6 /kg; IBM10) and 3.6*10 6 /kg (range: 1.5-6.8*10 6 /kg; IBM60) (P = n. s.). Time of leukocyte recovery was median d+11 (range: 9-16) and d+10 (range: 8-14) after 10 and 60 min infusion (P = n.s.).
Median leukocytes nadirs amounted to 0.24*10 9 /l for IBM10 and 0.29*10 9 /l for IBM60 (P = n.s.). The median duration of leukopenia ( o 1.00*10 9 /l) lasted 6d for both groups (range: 4-11d, IBM10; 3-9d, IBM60) (P = n.s.). Median platelet nadir was 0*10 9 /l for both cohorts (IBM10: range 0.0-11.0*10 9 /l, IBM60: 0.0-1.0*10 9 /l). The periods of thrombocytopenia ( ≤20.0*10 9 /l) were 5d (IBM10) and 6d (IBM60; range 3-12d, both; P = n.s.). The results for early engraftment were set at the points in time d+7, d+14, d+21, d+28. Donor PBMC chimerisms were median 21% (range: 8-34%), 48% (range: 29-53%), 62% (range: 55-73%) and 67% (range: 47-73%) in IBM10. The level of PBMC chimerism for IBM60 were 11% (range: 0-34%), 42% (range: 20-48%), 60% (range: 52-74%) and 62% (range: 44-81%) (P = n. s., each). Donor granulocyte chimerisms were median 33% (range: 11-83%), 99% (range: 58-100%), 100% (range: 81-100%) and 100% (range: 82-100%) in IBM10, respectively. The granulocyte chimerism in IBM60 amounted to 34% (range: 3-87%), 96% (range: 91-100%), 98% (range: 89-100%) and 67% (range: 94-100%) (P = n.s., for all time points). Conclusion: Our data suggest that modification of the HSC infusion rate has no impact on the early granulocyte and PBMC engraftment. Whether this is also true if grafts with low numbers are used has to be determined in subsequent studies. Disclosure of Interest: None declared. Introduction: The cure rate of childhood acute lymphoblastic leukemia (ALL) has improved considerably and approaches 80% today. However, the outcomes of patients who suffer from leukemic relapse remain unsatisfactory. Despite the high cure rate of children and adolescents with ALL a subgroup of patients benefit from allogeneic HSCT. Allo HSCT remains the standard treatment for intermediate/high risk AML patients. Material (or patients) and methods: Forty-two patients, ALL = 30 and AML = 12 age 1 to 20 years with median age 11.5 years, M/F = 19/23(M/F ALL = 14/16, AML = 5/7) underwent SCT in our hospital (from 2012-2015) . Forty-one patients transplanted Allo HSCT and 1 pt AML Auto HSCT. Conditioning regimens consisted of Busulfan (IV)+Cyclophosphamide for Allo and Cyclophosphamide+VP16 +Cytarabine for Auto HSCT. Peripheral blood (PB) was the source of progenitor cells in 34 patients, Bone marrow (BM) in 7 patients and cord blood in one patient. In Allo HSCT, 37 patient transplanted 6/6 matched and 4 patients 5/6 matched.GVHD prophylaxis regimen was cyclosporine+Mtx. All patients engrafted.
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Results: In allogeneic PBSCT ALL patients' median time to absolute neutrophil count (ANC)40.5 × 10 9 /L was 11 days, and the median time to platelet count420 × 10 9 was 14 days vs 18 and 22 days in Allo BM ALL patients. In allogeneic PBSCT AML patients median time to ANC4 0.5 × 10 9 /L was 13 days, and the median time to platelet count420 × 10 9 was 15 days. (All patients with AML transplanted with PB). At present 32 pts are alive (24 ALL, 8 AML) and 10 pts died due to ARDS, VOD, hemorrhagic stroke, sepsis and relapse. TRM was 9.5% at 100 days. Median time of death after transplantation was 165 days in ALL and 145 in AML. In Allo PBSCT ALL patients hospitalization period were 38 days vs. 46 in Allo BM ALL patients. Acute GVHD appeared in 80% pts. Chronic GVHD appeared in 48% pts. With a median follow-up of 15 months (3-41 months) after transplant the event-free survival were 74% and three years overall survival 78% in ALL patients. A median follow-up of 26.5months (6-38months) after transplant the event-free survival were 70% and three years overall survival 67% in AML patients. disease, with 5 year OS of only 15%. In the autologous setting, the 5 year OS was 44%. The main reason for mortality was relapse of the primary disease. Conclusion: HSCT is a well-established, justified and proven therapeutic option for AML patients, especially for patients in CR and appropriate risk profile. Still there is much to be done, maybe on the field of the initial treatment, conditioning protocols, or the management of GvHD. Introduction: High dose chemotherapy with autologous hematopoietic stem cell transplantation (aHSCT) is a promising approach for treatment of aggressive multiple sclerosis (MS). The most widely used conditioning regimens worldwide are the intermediate intensity BEAM+ATG and the low intensity cyclophosphamide/ATG, often reported as "Lymphoablative" as opposite to "Myeloablative" with reference to all the others. Outcome analysis of either single center series or Registry cohorts showed no advantage in using high intensity regimens, assuming that Myeloablative regimens are supposed to have a high transplant-related toxicity and a similar therapeutic impact on an Autoimmune Disease. We report here two successful aHSCT in very active MS forms using two intermediate intensity, myeloablative regimens. Material (or patients) and methods: Case 1. A 33 years old woman with aggressive MS and advanced disability (EDSS 6.5) was enrolled in a transplant program and planned to receive a BEAM/ATG conditioning regimen. A severe anaphylactic reaction occurred after BCNU infusion, requiring her transfer to ICU. After her return to BMT Unit we decided to finalize the conditioning regimen with just Melphalan, without ATG. Case 2. A 27 years old woman with relapsing remitting MS and moderate disability (EDSS 4.5) was also planned to receive a BEAM/ATG conditioning regimen. The rectal swamp collected upon admission showed a Carbapenems-Resistant Klebsiella Pneumoniae (KPC); therefore we decided to exclude melphalan and ATG from the conditioning regimen. Results: Complete engraftment occurred in a normal range for both patients;. no viral reactivations nor major adverse events after transplant were shown. Patients underwent periodic follow-up after HSCT for 6 years and 18 months, respectively. Both patients didn't show any clinical relapses, disability progression nor new lesions at MRI (NEDA3 negative); clinical assessment showed an EDSS score improvement (from 6.5 to 5.5 and from 4.5 to 4.0, respectively) in both patients. Conclusion: Despite the administration of a purely myeloablative regimen and the lack of ATG, both patients experienced a full neurological response and a very good hematological tolerability. The optimal conditioning regimen for MS is still to be defined. Disclosure of Interest: None declared.
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Immune neutropenia mimicking graft failure after granulocyte transfusions and allogeneic stem cell transplantation in a child severe congenital neutropenia B. Kremens Introduction: Children with Severe Congenital Neutropenia (SCN), an inborn failure of granulopoiesis with recessive inheritance, suffer from life-threatening infections even under treatment with G-CSF. Allogeneic stem cell transplantation is the only curative measure. Material (or patients) and methods: Case report A 2-year-old girl with SCN (heterogeneous missense mutation in exon 4 of ELANE gene) developed, although under treatment with G-CSF, an acute appendicitis with perforation. She survived under antibiotics, 3rd party donor granulocyte transfusions and after surgery. Her bone marrow cytology at that time showed an arrest of granulopoietic precursors at the level of promyelocytes, increased eosinophils and normal erythropoiesis and thrombopoiesis, the characteristic BM picture found in SCN. Having survived this event, she received peripheral hematopoietic stem cells from a 9/10 matched unrelated donor after conditioning with fludarabin, thiotepa, treosulfan and ATG at 2 years and 10 months of age. The graft was manipulated to contain 3.3 x 10E6 CD 34+ cells/kg and 8.4x 10E6 CD 3+/kg. Ciclosporin A was given for GVHD prophylaxis, G-CSF was instituted from day +4). Results: Hematopoietic recovery: for platelets420/nl day 11; 450/nl day 12; for leukocytes41.0/nl day 12. PMNs rose to 40.5/nl on day 14, reached a maximum of 4.6/nl on day 16, and then declined to 0 -0.01/nl on day 23 at which level they remained even under G-CSF treatment. Bone marrow cytology at this time showed exactly the same arrest of granulopoiesis at the level of promyelocytes, increased eosinophils and fully recovered erythro-and megakaryopoiesis as before SCT. However, graft failure was ruled out as the BM cells expressed 100% donor chimerism. In search of an etiology, antibodies against granulocyte antigen HNA-2 (CD 177) were detected at titers of41:4,000. Plasmapheresis was started 47 days post SCT. The titers decreased to 1:2,000 after the first, to 1:2 after the 4th, and to 1:1 or 0 after the 9th (and final) plasmapheresis. Peripheral PNM counts increased to 41.0/nl after the 4th plasmapheresis, oscillated somewhat during 3 weeks and remained within a range of 1.0 to 3.1/nl since then. The patient successfully tackled a skin aGvHD (stage 4), CMV reactivation, ADV infection and interstitial pneumonia, and is now alive, thriving and immunocompetent, at 3 years post SCT, enjoying stable PNM counts. Conclusion: Granulocyte transfusions -needed to surmount an appendicitis -apparently led to immunization against HNA-2 in this child with SCN, either because she was one of the 3% individuals who lack this glycoprotein, or because she has never expressed it since the very beginning of her embryonal granulopoiesis due to her underlying SCN. The bone marrow cytologies of SCN and of alloimmune neutropenia looked undistinguishably similar. The complete chimerism led us to correctly diagnose and treat this post SCT enigma. Disclosure of Interest: None declared.
Introduction: Fluorine-18-Deoxyglucose Positron Emission Tomography Scan (PET) is a valuable diagnostic tool in Hodgkin lymphoma (HL). In the autologous haematopoietic cell transplantation (AHCT) setting, the prognostic value of pre-AHCT PET has been established by current studies, but the significance of early post-AHCT PET negativity has not yet been fully investigated. Material (or patients) and methods: In this retrospective, single center analysis, we evaluated the role of early post-AHCT (+3 to +6 months) metabolic remission in 58 consecutive HL patients (pts), aged 36 (13-62), who underwent AHCT during 2009-2014, for primary refractory (43), or relapsed disease (15) post 3 (1-9) lines of treatment. Disease status was chemosensitive to salvage treatment in 29 pts. The conditioning regimen was BEAM (17) or Busulfan-based (Busulfan 9.6 mg/kg, Etoposide 400 mg/m 2 and Melphalan 140 mg/m 2 , BuEM) (41). Results: Forty eight pts were evaluated by PET at +3 to +6 months (m) while the rest had disease progression by CT assessment (7 received additional involved field irradiation post-AHCT, as part of the treatment plan). Thirteen pts had positive and 35 negative PET. The overall early-response rate by PETevaluation was 73% (35/48 evaluated pts). In univariate analysis, overall survival (OS) and disease free survival (DFS) were superior in pts achieving early post-AHCT negativity (5y-OS 89% vs 29%; P = 0.007, 5y-DFS 78% vs 22%; P = 0.012). Patients' characteristics according to the conditioning regimen were similar in terms of disease phase and chemosensitivity (x 2 test). With a median follow up of 29 (2-76) m (BEAM 18, BuEM 45 m), the estimated 5-year DFS and time to progression (TTP) were similar in both conditionings. At last follow-up 40/48 (83%) pts were alive and 32 (66%) in CR. Treatment related mortality was low with both regimens (1%). Overall survival was high and similar in both conditioning groups, with no significant difference in DFS. In multivariate analysis disease phase, chemosensitivity, type of conditioning and early-PET evaluation were incorporated. Early PET-negativity was the only significant factor correlated with superior OS (P = 0.02). In terms of DFS, disease chemosensitivity identified as significant favorable factor (P = 0.02), while early metabolic remission was of borderline significance (P = 0.06). Conclusion: With the limitations of this retrospective analysis, early metabolic complete remission, along with disease chemosensitivity to salvage treatment, seems to be the most significant predictor in HL pts for improved overall survival and time to disease progression. Both conditioning regimens proved to be similarly efficacious and feasible, remaining the key players for a successful outcome of AHCT in lymphomas. Additionally, early PET can optimize the outcome in HL patients regarding the need for post AHCT consolidation in the era of novel targeted agents. 2 ) before transplantation. CEAC is considered as the preparative regimen that including additional local supplementary radical radiotherapy for patients with large mediastinal masses. The total four weeks biological treatment including five days of IL-2 and two days of rest, that was applied for the patients with hematopoietic recovery. The patients who showed CR before and after transplantation adopted consolidation treatment every three months, of which total courses are 4 to 6 and 6 to 8. Patients who showed PR following transplantation accepted autologous transplantation in 3 months after transplantation. Patients who presented NR or RE accepted allogeneic transplantation. Results: All patients acquired hematopoietic reconstitution, in which the average reconstituted time of ANC was +11.6 d and PLT was +14.2 d respectively. The main complications are tolerable, including gastrointestinal reactions (82.9% of incidence rate), oral mucositis (51.2% of incidence rate) and mild liver damage (19.55% of incidence rate) which does not affect the progress of sequential treatment. The median follow-up time was 54 months (range 6-97 months). Among CR1 survivors, 55 patients are disease-free (84.6%) and 10 survivors with disease(15.6%) and no death; 20 CR2 survivors are disease-free (71.4%), 15 CR2 survivors with disease (15.2%) and 5 deaths (17.8%); 8 PR survivors are disease-free (61.5%), 2 PR survivors in disease (15.4%) and 3 deaths (23.1%); 2 NR survivors are disease-free (20%), 3 NR survivors with disease (30%) and 5 deaths (50%). The overall survival and progression-free survival of 5 years for all patients are 78.9% (95% CI 48.1-78.5%) and 65.3% (95% CI 52.3-74.6%), respectively. Conclusion: Sequential ASCT showed its efficacy in treatment for aggressive non-Hodgkin's lymphoma by increasing the cure rate of disease. Disclosure of Interest: None declared.
